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CORRECTIONS PAGE 
1. A list of abbreviations has been added to the thesis. (Page 16) 
2. The list of full publications associated with this thesis has been divided into 
2 – publications arising directly from the thesis, and subsequent publications 
arising from the work of this thesis (page 30) 
3. Proper nomenclature has been used for the great saphenous and small 
saphenous vein, and reference included for this (page 40) 
4. A section has been included to mention the use of radiofrequency ablation 
(RFA) as an option for endovenous management of varicose veins (page 
61) 
5. Legends for tables and figures have been expanded  
6. Spelling mistakes and omissions have been corrected 
7. Text has been introduced to clarify the number of patients and limbs 
assessed in the results of study 3 (page 108) 
8. Text has been introduced to specify “major complications” in the results of 
study 3 (page 113) 
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9. Clarification has been made on the duration of EVLTAP procedure to (page 
148) 
10. The section on critique has been removed, and the critique has been 
incorporated in the discussion of the relevant study. 
11. Appendices have been added at the end to show the VCSS, AVVQ and SF 
36 forms 
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ABSTRACT 
Varicose veins are dilated and tortuous subcutaneous veins, which affect a 
significant proportion of adults. They cause physical and emotional symptoms, and 
affect quality of life in sufferers. The management of varicose veins has evolved 
since the early 20th century, when Babcock described what has now become the 
gold standard surgical treatment. Perhaps the most significant evolution is the 
development and popularisation of minimally invasive therapy, especially 
endovenous laser ablation (EVLA) in the last two decades. This thesis focuses on 
the optimisation of outcomes in the management of this very common condition. 
Four studies were performed to evaluate varicose vein treatment modalities and 
outcomes, investigating key issues such as: the proportion of patients suitable for 
EVLA; optimisation of EVLA; how does EVLA compare with surgery, and what is 
the effect of prophylactic antibiotics on wound complications following surgery? 
Approximately 60% of varicosities are suitable for EVLA, with vein anatomy being 
the commonest cause for unsuitability. The concomitant performance of 
phlebectomies at the time of EVLA was shown to be feasible, acceptable to 
patients, and improved outcomes. EVLA was shown to be clinically effective, and 
eliminated the early quality of life limitations of surgery. Wound complications 
following surgery were found to be significantly reduced by the use of prophylactic 
antibiotics.    
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GLOSSARY OF ABBREVIATION 
  
95% CI  
 
95% confidence interval  
ALTV  
ASEPSIS 
Anterior lateral thigh vein 
 Wound scoring system (see text) 
AVVQ  Aberdeen varicose veins 
questionnaire 
BMI  
CEAP 
Body mass index  
Clinical aEtiologic Anatomic 
Pathophysiolic Score 
CVI  Chronic venous insufficiency  
DUS  Duplex ultrasound   
DVT  Deep vein thrombosis  
EVLA  
EVLT 
 
EVLTAP 
Endovenous laser ablation  
Endovenous laser therapy 
(synonymous with EVLA) 
Endovenous laser therapy with 
concomitant ambulatory 
phlebectomy 
g  gram - unit of weight (may be 
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prefixed by k - kilo, m - milli)  
GA  
GP 
General anaesthetic  
General Practitioner 
GSV  Great saphenous vein   
IQR  Inter-quartile range  
J  Joule - unit of energy  
L 
 
LA 
Litre - unit of volume (may be 
prefixed by m - milli)  
Local anaesthetic 
M  
 
 
MMP 
NHS  
OR 
QoL 
RCT 
 
RFA 
SFJ 
Metre - unit of length (may be 
prefixed by c - centi, m - milli, n - 
nano)  
Matrix metallo prateinase 
National Health Service 
Odds ratio 
Quality of life 
Randomised Clinical (controlled) 
Trial 
Radiofrequency Ablation 
Sapheno Femoral Junction 
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SF36 
 
 
 
 
 
 
SPJ 
SSI 
SSV 
STD 
TIMP 
 
VAS 
VCSS 
 
Short form 36 (Domains: PF-
Physical Function; RP-Physical 
Role; BP-Bodily Pain; GH-General 
Health; Vit-Vitality; SF-Social 
Function; RE-Emotional Role; MH-
Mental Health 
 
Sapheno popliteal junction 
Surgical site infection 
Small saphenous vein 
Sodium tetradecyl sulphate 
Tissue inhibitor of Matrix Metallo 
Proteinases 
Visual analogue scale 
Venous clinical severity score 
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SUMMARY OF THESIS 
Introduction 
Varicose veins are dilated, tortuous, and palpable subcutaneous veins. They are 
common and affect up to a third of adults in the Western world. Varicose veins 
cause symptoms and complications, cosmetic concerns, but more importantly, 
cause health - related quality of life limitations. The gold standard treatment of 
varicose veins is surgery. Babcock introduced surgery for lower limb varicose veins 
in the early 1900s, and since then the procedure has undergone various 
modifications and evolved to become a clinically effective therapy for varicose 
veins. It improves quality of life, and could be cost effective in the day case setting. 
There are however complications and limitations to standard surgery, including the 
need for a general anaesthetic in most cases, as well as wound related issues. 
In the mid to late 1990s, there was a major breakthrough in the treatment of 
varicose veins with the introduction of minimally invasive options. Arguably, the 
greatest revolution in these options has been with endovenous laser ablation 
(EVLA) first described by Bone et al. This uses diode laser energy to cause 
thermal destruction of the vein from within, resulting in a non thrombotic occlusion. 
The procedure has proven to be safe, effective and associated with minimal 
significant complications, and compares very favourably with surgery. Moreover, it 
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can be performed in the office setting under local tumescent anaesthetic. One 
minor “set back” of laser therapy is the requirement for subsequent adjunctive 
therapies in 30% - 99% of patients, to deal with branch varicosities. Also not every 
varicose vein may be suitable for laser ablation. 
This thesis focuses on a number of issues which are key to the optimisation of 
lower limb varicose vein treatment: 
What proportion of patients with varicose veins can undergo EVLA? 
How can EVLA be optimised for efficacy, reduce the need for subsequent 
procedures, and yet preserve the excellent patient experience? 
How does EVLA compare with surgery? 
Can the use of prophylactic antibiotics reduce wound complications following 
surgery for varicose veins, thereby eliminating one significant problem with 
standard surgery? 
Methods 
Four related trials were designed to investigate these issues. The EVLA suitability 
study interrogated the waiting list for day - case varicose vein surgery and carried 
out venous doppler ultrasound on 150 randomly selected patients, based on very 
rigid suitability criteria, which were derived from a review of the then current 
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literature on EVLA practice. A prospective review of the waiting list for vv surgery in 
a university hospital was performed between June 2004 and May 2005. The period 
represented the first year of commencement of EVLA at the centre. I50 
sequentially selected patients listed for unilateral primary sapheno femoral junction 
(SFJ) ligation, stripping of the GSV and avulsions were invited for duplex 
ultrasound scan (DUS) to assess suitability for EVLA. Suitability criteria included: 
Isolated SFJ / GSV incompetence, absence of major incompetent thigh branch, 
peri genicular GSV diameter greater than 5mm, as well as patient acceptance of 
local anaesthetic procedure.  
The second study was a prospective observational study investigating the 
feasibility of performing concomitant ambulatory phlebectomy / avulsions along 
with EVLA under tumescent anaesthetic (a procedure were termed EVLTAP). 67 
patients (70 limbs) with varicosities of the great saphenous vein, confirmed by 
duplex scan (DUS) underwent EVLTAP. Pain severity was assessed on days 1, 4 
and 7 using a visual analogue scale (VAS) of 0 to 10. Clinical and DUS 
assessments were carried out at 1, 6 and 12 weeks (no DUS at 6 weeks). Residual 
varicosities were managed by re-do phlebectomy or sclerotherapy. Patients’ 
satisfaction with cosmetic appearance and with the overall treatment procedure 
was assessed at 3 months using a VAS rating between 0 and 10. 
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Study three was a non randomised trial comparing standard surgery with EVLA.  
Two non-randomised groups were studied. The EVLA group comprised 70 
patients, median age 49 (inter quartile range [IQR] 35-58) years. The surgery 
group was comprised of 62 patients, median age 49, (IQR 35-61) years. Patients 
were assessed prior to, and at 1, 6, and 12 weeks post-procedure using the 
following quality of life and clinical assessment tools: Short Form 36 (SF36), 
Aberdeen Varicose Veins Questionnaire (AVVQ), and the Venous Clinical Severity 
Score (VCSS).  
The final study was a randomised controlled trial investigating the effect of a single 
dose of antibiotic in preventing groin wound complications in patients undergoing 
varicose vein surgery. 443 patients undergoing varicose vein surgery randomly 
received a single prophylactic dose of 1.2g co-amoxiclav (219 patients) or no 
antibiotic (224 patients). Patients completed a wound diary on postoperative days 
3, 5, 7, 9 and 10 using an adapted ASEPSIS method of postoperative wound 
assessment, and were reviewed at 14 days. 
Results 
Study 1: 482 patients were added to the waiting list (328 women). 339 were listed 
for GSV surgery. Of those invited for DUS, 112 (74.6%) attended.  63 patients 
(56%) were suitable, while 49 (44%) were unsuitable.  
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Of unsuitable patients, 39% had incompetent thigh branch, 20% had peri genicular 
GSV less than 5mm, 12% wanted general anaesthetic and 2% preferred surgery. 1 
patient (2%) had no SFJ/GSV incompetence on DUS, and 24% were unsuitable for 
combined reasons. 
Study 2: 49 patients (70%) completed 12 weeks follow up. Median pain scores 
were 1.6 (IQR 0.2-4.8), 0.3 (0–1.4) and 0.2 (0–1.1) on days 1, 4 and 7 respectively. 
DUS demonstrated 69 (99%) and 47 (96%) occluded GSVs at 1 week and 3 
months respectively. Subsequent sclerotherapy or phlebectomy was performed on 
3 (4%) or 1 (1%) limbs respectively. Cosmetic satisfaction was 9.6 (median; IQR 
8.9–10) and overall satisfaction 9.8 (IQR 9.3–10). 
Study 3: Follow up at 1, 6 and 12 weeks was 100%, 77% and 70% following EVLT 
and 100%, 85% and 47% following surgery.  
SF36 scores were significantly better in the EVLA group at 1 week, (Physical 
Functioning, Role Physical, Bodily Pain, Vitality and Social Functioning domains) 
and at 6 weeks (Physical Functioning and Role Physical). At 12 weeks, no 
significant differences were evident between the groups.  
AVVQ scores were significantly better in the EVLA group at 6 and 12 weeks. VCSS 
scores were significantly improved in both groups at 12 weeks. 
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Study 4: Both groups were balanced at baseline. Patients receiving antibiotic 
prophylaxis had lower ASEPSIS wound scores on days 3, 5 and 7 (p=0.043, 0.032 
and 0.003 respectively), and lower total ASEPSIS scores (median [IQR] of 3 [0-9] 
versus 6 [0-15]; p=0.013). They were also less likely to consult their General 
Practitioner (16% vs. 24.3%; p=0.040) and receive antibiotics (4.7% vs. 13.5%%; 
p=0.002) postoperatively for wound related problems. Wound outcomes were 
worse with higher body mass index (BMI) (Odds Ratio [OR] 0.92, 95% CI 0.87-0.97; 
p=0.005), and current smoking (OR 0.5, 95% CI 0.3-0.9, p=0.03). Receiving 
prophylactic antibiotic conferred satisfactory wound healing (OR 2.2, 95% CI=1.3-
3.6; p=0.003). 
Conclusions  
The management of varicose veins has evolved since the 1900s. The last two 
decades have especially seen a tremendous advancement in management of 
varicose veins, particularly in endovascular techniques. The studies included in this 
thesis have explored important aspects of varicose vein management. At the time 
of performing the studies, just over half of all patients listed for primary varicose 
vein surgery were suitable for EVLA. As anticipated however, expertise has grown, 
indications have been expanded and more patients are now being offered EVLA 
and other minimally invasive treatments. 
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The EVLTAP procedure was designed to take away a clear limitation of EVLA in its 
early years: the need for subsequent interventions in the majority of patients. 
EVLTAP produced excellent results, was found feasible and acceptable, and 
clearly obviated the need for subsequent procedures in the short-term.  
EVLA and surgery provide similar Quality of Life and clinical improvements in 
patients with varicose veins. Standard surgical treatment of varicose veins 
however, is associated with QoL limitations in the early postoperative period. EVLA 
has been shown to remove the QoL limitations experienced by patients in the early 
surgical postoperative period.  
Another limitation of standard surgery is the risk of wound complications including 
infection. Antibiotic prophylaxis reduces wound-related problems following varicose 
vein surgery, and reduces the burden placed upon primary care by patients 
presenting with postoperatively wound problems. 
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1. INTRODUCTION 
Varicose veins are elongated, dilated and tortuous veins. They are defined as 
dilated palpable subcutaneous veins, generally larger than 4mm in the upright 
position (Porter and Moneta 1995). The word ‘varicose’ is derived from the Latin 
word ‘varix’, which means twisted. The adoption of the erect position by man is 
thought to have greatly influenced the development of venous diseases of the 
lower limbs. Impairment of return of venous blood to the heart against gravity as a 
result of the erect position, results in the development of acute venous thrombosis, 
varicose veins, and chronic venous insufficiency (van den Bremer and Moll 2010). 
Varicose veins have been recognised for thousands of years, being mentioned in 
the papyrus of Ebers around 1550BC and also by Hippocrates the father of modern 
medicine. 
1.1. Incidence and Epidemiology 
Venous disease, including varicose veins, is common in industrialized and Western 
populations (Beebe-Dimmer, Pfeifer et al. 2005). The prevalence of varicose veins 
is very low in African, Asian and Australasian Aboriginal populations, although 
immigrants from these regions generally take on the same risk level as their host 
environment (Carpentier and Priollet 1994).  
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The estimates of varicose veins prevalence varies very widely from 2% - 56% in 
men and <1% - 73% in women (Beebe-Dimmer, Pfeifer et al. 2005). This variation 
is based, not only on real predisposing causes (which will be addressed later on), 
but also on differences in definitions and study methodology. In the late 1990s in 
the United Kingdom, the Edinburgh vein study found a prevalence of 39.7% in men 
and 32.2% in women (Evans, Fowkes et al. 1999). This figure is still widely quoted 
in current literature.  
1.2. Aetiology 
The Aetiology of varicose veins is unclear, although more understanding of the 
pathogenesis has been made in recent years. The pathogenesis of varicose veins 
is discussed later in this section. There are recognized factors which predispose to, 
or are associated with varicose veins. Perhaps the most important of these factors 
are sex, age, family history, and pregnancy (Lim and Davies 2009). These and 
other risk factors, as well as the evidence for them are discussed below.   
Sex 
There is no consistency in the literature as to gender differences in prevalence of 
varicose veins. Several studies have shown that varicose veins appear to be more 
prevalent in women (Brand, Dannenberg et al. 1988, Callam 1994, Bergan, 
Schmid-Schonbein et al. 2006). This finding is however not supported by other 
population based studies, which have shown higher prevalence in men (Evans, 
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Fowkes et al. 1999). Prevalence studies carried out among patients presenting to 
hospital with varicose veins, show a higher prevalence in women, and this has 
been explained by the fact that women are more likely than men, to report varices 
and present to their doctors, (Beale and Gough 2005, Beebe-Dimmer, Pfeifer et al. 
2005). The Edinburgh vein study (Evans, Fowkes et al. 1999), the Italian 24 Cities 
Cohort study (Chiesa, Marone et al. 2005), and a Bulgarian cross sectional survey 
(Zahariev, Anastassov et al. 2009) showed a higher prevalence of telangiectasia in 
women, but a higher prevalence of trunk varicosities in men. This would indicate 
that perhaps, it is the presence of telangiectasia as opposed to trunk varices, which 
makes varicose veins more common in women. That said, there have been studies 
which showed no sex differences in varicose vein prevalence (Franks, Wright et al. 
1992, Komsuoglu, Goldeli et al. 1994). 
In studies which support a higher prevalence in women, it is presumed that 
pregnancy is a major contributory factor (Stansby 2000). Some evidence suggests 
that parous women have a higher incidence of varicose veins compared with 
nulliparous women, and that multiparous women have the highest risk for the 
development of varicose veins (Dindelli, Parazzini et al. 1993, Jukkola, Makivaara 
et al. 2006). More recent evidence however, has not supported this. In a study of 
583 extremities in women with uncomplicated primary varicose veins (previous 
varicose vein surgery and history venous thrombosis excluded), Englehorn and 
  
35 
 
colleagues performed colour duplex ultrasound scans and analysed their findings 
as a function of number of pregnancies. There was no significant association 
between parity and the presence of primary varicose vein (Engelhorn, Cassou et 
al. 2010).  
Pregnancy is associated with a number of physiologic changes which likely 
contribute to the development of venous distension and potentially varicose veins. 
The significant increase in blood volume during early pregnancy (Bernstein, Ziegler 
et al. 2001) increases the strain on venous capacitance, which may lead to venous 
dilatation. As pregnancy advances, there is increased intra abdominal pressure 
and impedance of central venous return arising from foetal growth and weight gain 
(Chapman, Abraham et al. 1998). This may also contribute to the increased 
prevalence of varicose vein in pregnancy. It has been observed however, that 
varicose veins often develop in pregnancy prior to any significant  increase in 
uterine size (Beebe-Dimmer, Pfeifer et al. 2005). This may therefore suggest that 
other factors besides pressure from the gravid uterus may be important. The effect 
of increased levels of hormones in pregnancy is an important one. The hormones 
relaxin, oestrogen and progesterone (Vin, Allaert et al. 1992, Chapman, Abraham 
et al. 1998, Lenkovic, Cabrijan et al. 2009) are the principal players in this respect, 
having effects on venodilatation, venous stasis, valvular dysfunction, and possibly 
weakening the integrity of venous wall. 
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Geography and Race 
Varicose veins are generally more prevalent in more developed, industrialised 
countries than in underdeveloped countries (Beebe-Dimmer, Pfeifer et al. 2005). A 
study from the late 1960s found that varicose veins were 5 times more prevalent in 
England than in Egypt (Mekky, Schilling et al. 1969). Although migrant populations 
generally take on the risk levels of their host countries (Carpentier and Priollet 
1994), studies from multi-ethnic populations show a significant difference in 
prevalence rates among different ethnic groups. The San Diego population study 
(Criqui, Jamosmos et al. 2003) for example, showed a higher prevalence of visible 
varices in non Hispanic Whites, than in Hispanics, African-Americans, and Asians. 
The underlying cause for the racial and geographic variation is yet to be elucidated, 
but may relate to genetic factors affecting vein wall integrity.  
Age  
There is universal agreement that the prevalence of venous disease increases with 
increasing age (Evans, Fowkes et al. 1999, Beebe-Dimmer, Pfeifer et al. 2005, 
Chiesa, Marone et al. 2005). It is most likely that the increasing prevalence with 
age is the result of increased pressure on superficial veins due to the weakening of 
calf muscles coupled with the gradual deterioration of vessel walls over time 
(Beebe-Dimmer, Pfeifer et al. 2005). In addition to varicose veins, the prevalence 
of chronic venous insufficiency also increases with age, especially noticeable in 
men (Fowkes, Evans et al. 2001). Brand et al (1988) found in their survey in the 
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USA, that the prevalence of varicose veins among people younger than 30 years 
was less than 1% for men and less than 10% for women. However, from age 70 
years and older, the estimates increased substantially to 57% and 77%, in men 
and women respectively. 
Family History and Genetics 
There is some evidence to support genetic and familial predisposition to varicose 
vein development. The risk of developing varicose veins has been reported to be 
90% if both parents suffered from this disease, 25% for men and 62% for women 
with one affected parent and 20% when neither parent was affected (Cornu-
Thenard, Boivin et al. 1994). 
Although no specific genes have been identified, studies have described familial 
aggregation of manifestations of venous disease (Arnoldi 1958, Berard, Abenhaim 
et al. 2002, Lee, Evans et al. 2003). In a study of Japanese women, 42% of 
subjects with varicose veins reported a positive family history compared with just 
14% of women without disease (Hirai, Naiki et al. 1990). In a Finnish study of 40 – 
60 year old men and women with varicose veins, the odds ratio associated with 
self-reported positive family history, was 4.9 (Laurikka, Sisto et al. 2002). The 
finding was similar in a Turkish study, which noted an overall risk ratio of 4.4 
associated with a positive family history (Komsuoglu, Goldeli et al. 1994).  
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These results have to be interpreted with some degree of caution. Firstly, most 
have been based on self reporting, with no independent researcher verification 
(Beebe-Dimmer, Pfeifer et al. 2005). Secondly, there may be recall bias, and 
people with venous disease are more likely to give a family history, but also more 
likely to display a higher proportion of misclassification and false positive report 
(Ahti, Makivaara et al. 2010). There is a hereditary component of varicose veins, 
but the effect is in all likelihood, much less than reported in literature (Ahti, 
Makivaara et al. 2009).    
Obesity 
Several studies have shown that obesity is a risk factor for development of 
varicose veins. Although some studies have found this effect in both men and 
women (Abramson, Hopp et al. 1981, Callam 1994, Sisto, Reunanen et al. 1995), 
the effect appears to be more so in women (Brand, Dannenberg et al. 1988, 
Kontosic, Vukelic et al. 2000, Lee, Evans et al. 2003). Obese women (BMI ≥ 30 
Kg/m2) were 3 times more likely to report varicose veins, according to a 
retrospective cohort Dutch study (Seidell, Bakx et al. 1986).   
The exact pathogenic mechanism for the effect of obesity on the development of 
varicose veins has not been defined. The effect may be due to the increased intra 
abdominal pressure in the obese (Noblett, Jensen et al. 1997), which results in 
decreased blood flow in pelvic veins, and therefore increased lower limb venous 
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pressures (Fowkes, Lee et al. 2001). This is supported by a recent study in New 
Zealand which showed worse venous filling index (a good marker of reflux on air 
plethysmography) in the obese population, especially in women (van Rij, De Alwis 
et al. 2008). It has also been suggested that since the effect of obesity is more 
profound in women, there may be a confounding effect of pregnancy and parity or 
to the effect of circulating hormones (Lee, Evans et al. 2003, Beebe-Dimmer, 
Pfeifer et al. 2005). In a study of postmenopausal women in Italy however, the 
higher prevalence of varicose veins in obese women, was found to be independent 
of sex hormone levels (Iannuzzi, Panico et al. 2002).  
Other risk factors 
There are other risk factors associated with varicose veins, although these may not 
be as important as the factors discussed above, and evidence for them is at best 
tenuous. These factors include:  
Sedentary occupations and those associated with prolonged standing (Stvrtinova, 
Kolesar et al. 1991) 
Low fibre “Western type” diets result in constipation, straining at stool, and high 
venous pressure (Burkitt, Townsend et al. 1976). The Edinburgh vein study found 
lower fibre intake, longer intestinal transit time and straining at stool were 
associated with an increased risk of trunk varices, but only in men (Fowkes, Lee et 
al. 2001) 
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Height was associated with a positive risk for varicose veins (Franks, Wright et al. 
1992, Laurikka, Sisto et al. 2002, Lee, Evans et al. 2003). This may be related to 
increased hydrostatic pressure.  
Smoking (Gourgou, Dedieu et al. 2002), history of high blood pressure (Clark, 
Harvey et al. 2010), use of hormone replacement therapy (Jukkola, Makivaara et 
al. 2006), lower limb fracture (Lindhagen, Bergqvist et al. 1985) are some of the 
other risk factors that have been associated with the development of varicose 
veins.  
1.3. Pathology 
Anatomy of the lower limb venous circulation 
The detailed anatomy of the lower limb venous circulation is well presented in 
anatomy texts and is not included in this work. However, a brief description is 
outlined below. There are 3 systems of veins that drain the lower limb: the 
superficial, deep, and perforator systems.     
The Superficial veins are located in the superficial compartment of the limb, 
external to the deep fascia. It is a low pressure compartment, and the veins of this 
compartment drain the skin and superficial tissues. The 2 main veins of this system 
in the lower limbs, are the great saphenous vein (GSV; previously referred to as 
the long saphenous or greater saphenous vein), and the small saphenous vein 
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(SSV; previously referred to as the short or lesser saphenous vein).The change in 
nomenclature was agreed by an international interdisciplinary consensus 
committee in Rome, in September 2001, to eliminate confusion over previous 
nomenclature (Caggiati, Bergan et al. 2002). The GSV commences from the 
medial side of the dorsal venous arch of the foot and ascends in front of the medial 
malleolus, running upwards on the medial side of the leg. It passes behind the 
knee and curves forward along the antero-medial thigh, and perforates through the 
saphenous opening in the deep fascia to join the femoral vein in the upper thigh.  
The SSV arises from the lateral side of the dorsal venous arch of the foot, and runs 
upwards, behind the lateral malleolus. It follows the lateral border of the tendo 
calcaneus and then runs up the middle of the back of the leg. It pierces the deep 
fascia, passing between the 2 heads of the gastrocnemius muscle to join the 
popliteal vein anywhere between the back of the knee and the upper posterior 
thigh. It may also terminate by joining the GSV. There are several anastomotic 
branches that run upward and medially from the SSV to join the GSV.    
The Deep veins are located deep to the deep fascia, and run with the main arteries 
(known as venae comitantes). They drain the muscles and deeper tissues, and 
provide the vast majority of venous drainage of the lower extremity. The venae 
comitantes of the anterior and posterior tibial arteries join in the calf to form the 
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popliteal vein, which ascends to become in turn, the superficial femoral vein, the 
common femoral vein, then iliac vein and inferior vena cava.      
Perforator veins pierce the deep fascia and connect the superficial to the deep 
system. They have valves that allow blood to flow from the superficial to deep 
systems. A few named perforating veins are fairly constant in location and are 
named only as vague groupings. The old nomenclature included Hunter’s 
perforator in the mid thigh, Dodd’s perforator in the distal thigh, Boyd’s perforator at 
the knee, and Cockett’s perforators in the distal medial calf and ankle.  
Calf pump mechanism 
The passage of blood upward from the feet against gravity depends on a complex 
array of valves and pumps. Muscle pumps of the calf and foot provide the motive 
force for venous return. This is frequently called the calf muscle pump or musculo-
venous pump and is thought to function as the peripheral heart. The pump of the 
calf muscle chamber is the gastrocnemius and soleus muscles. There is a network 
of very distensible thin-walled veins within the muscles. Each segment of the calf 
muscle pump works in the same way as the hand bulb of a sphygmomanometer. 
Inflow to a segment of deep vein is through intake valves from perforating veins as 
well as from the deep vein segment below. Outflow is through an outflow valve to 
the deep vein segment above. Squeezing of the vein segment occurs when muscle 
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contraction (muscular systole) increases the pressure within a fascial muscle 
compartment. The valves of the perforator veins close to prevent blood from 
passing into the superficial veins, therefore blood is squeezed upwards in the deep 
veins, towards the heart. When the muscles relax (muscular diastole), the pressure 
in the deep muscular compartment and the deep veins is temporarily lower than 
that in the superficial compartment; blood therefore flows from the superficial to the 
deep veins through the perforators. Upon the next muscle contraction, the valves in 
the perforating veins close again, and blood is squeezed upwards in the deep 
veins towards the heart. 
 When the normal lower limb venous circulation is disturbed, varicose veins and 
chronic venous insufficiency result. The problem may affect the superficial, deep or 
perforator systems either singly or in combination. The prevailing theory is that 
valve reflux is important in the development of varicose veins. With valve reflux, 
there is retrograde flow of blood, causing venous stasis and hypertension, and vein 
wall dilatation, although the exact sequence in which these features occur is still 
subject to debate. 
Pathogenesis  
There is universal agreement that valve reflux is the principal determinant of 
varicose veins and chronic venous insufficiency (Beebe-Dimmer, Pfeifer et al. 
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2005). There is however no consensus as to whether primary valve incompetence 
is the initiating event in the pathogenesis, or is the result of vein wall dilatation. The 
evidence for each of these factors is examined below:  
Primary valvular dysfunction 
It is generally accepted that valve dysfunction with reflux leads to progressive 
venous insufficiency. One hypothesis proposes that the initiating event is valvular 
dysfunction, which causes reflux. Reflux then causes blood stasis and venous 
hypertension, which in turn damages the vein wall, leading to weakness and 
dilatation (Lim and Davies 2009). Reflux may occur in venous tributaries in the 
absence of axial reflux in the truncal, deep or perforator veins (Labropoulos, Kang 
et al. 1999). It has also been shown that primary venous reflux in both the 
superficial and deep veins can occur in an ascending (rather than retrograde) 
fashion, and can be local or segmental (Labropoulos, Giannoukas et al. 1997). 
These findings would indicate that saphenous vein reflux is not needed for primary 
varicose vein pathology to occur. Histology of valves from varicose veins show 
abnormalities / deformities and hypotrophy more frequently than valves from non-
varicose veins (Corcos, De Anna et al. 2000). Valves from varicose veins also 
contain less collagen and greater inflammatory activity than valves from adjacent 
non varicose vein segments (Psaila and Melhuish 1989, Ono, Bergan et al. 1998). 
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These findings suggest a role for primary valvular dysfunction in the initiation of 
varicose veins. 
Primary wall dilatation 
An alternative hypothesis than that above, is that the formation of varicose vein is 
secondary to defects in cellular and extracellular matrix components, which cause 
weakness and altered venous tone (Raffetto and Khalil 2008). This hypothesis is 
supported by several clinical and biochemical / histological findings. Reflux and 
varicose veins do not always start at the sapheno femoral or sapheno popliteal 
junctions and progress in a retrograde fashion. Therefore the same argument 
proposed for primary vein dysfunction may actually support the role of primary vein 
wall dilatation, as anterograde or ascending progression of disease is more likely to 
be caused by primary vein wall changes leading to secondary valve incompetence, 
than the other way round (Lim and Davies 2009). Also varicosities are frequently 
observed below competent valves, and venous dilatation is seen distal to a valve, 
rather than proximal, which would be the case if valvular incompetence preceded 
wall dilatation (Naoum, Hunter et al. 2007). Structurally, changes in the vein wall 
media, including smooth muscle cell proliferation, and extracellular matrix 
degradation are observed more commonly in varicose than in non-varicose veins 
(Aunapuu and Arend 2005, Elsharawy, Naim et al. 2007). Studies have also found 
an imbalance in the collagen:elastin ratio in both varicose and adjacent non 
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varicose segments of saphenous vein, compared with normal saphenous vein. 
These changes occurred prior to valve insufficiency (Gandhi, Irizarry et al. 1993, 
Wali, Dewan et al. 2003).  
The degradation of the extracellular matrix, which provides a structural framework 
of collagen, proteglycans, elastin, glycoproteins and fibronectin in which various 
cellular components are embedded, is likely to contribute to the weakening and 
dilatation of veins (Hobeika, Thompson et al. 2007, Lim and Davies 2009). The 
extracellular matrix homeostasis is regulated by a group of zinc-dependent 
endopeptidases called matrix metalloproteinases (MMPs) and their endogenous 
inhibitors, tissue inhibitors of metalloproteinases (TIMPs) (Somers and Knaapen 
2006, Hobeika, Thompson et al. 2007). Of the 23 MMPs that have been identified 
in humans, at least 14 of them are expressed in vascular tissues (Lim, Shalhoub et 
al. 2010).  Expression of various MMPs and TIMPs has been documented to 
varying degrees in varicose veins (Kockx, Knaapen et al. 1998, Kowalewski, 
Sobolewski et al. 2004), with expression in various layers of the vein wall 
(Gillespie, Patel et al. 2002, Kosugi, Urayama et al. 2003). Lim et al and others 
have noted MMP-TIMP imbalance in varicose veins (Badier-Commander, 
Verbeuren et al. 2000, Lim, Shalhoub et al. 2010). These finding suggest that 
MMPs may affect all layers of the venous wall, including the extracellular matrix 
structure, leading to wall degradation and varicose vein formation. However, over 
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expression of MMP-2 and MMP-9 has been shown to occur with increased 
magnitude and duration of venous wall tension. Furthermore, the MMP-2 induced 
by increased wall tension, caused significant venous relaxation (Raffetto, Ross et 
al. 2007, Raffetto, Qiao et al. 2008). These findings may suggest that the 
production of MMPs, which increases extracellular matrix degradation and venous 
relaxation, may in fact be secondary to blood stasis and venous hypertension. 
MMPs have also been implicated in smooth muscle cell dysfunction. In a study of 
smooth muscle cells cultured from varicose veins, there was an imbalance of 
collagen production, with increased type I, but suppressed type III. The mechanism 
involved in this collagen degradation is likely linked to the expression of MMP-3. 
(Sansilvestri-Morel, Rupin et al. 2005). Other studies have found decreased 
apoptosis in smooth muscle cells from varicose veins. Apoptosis (programmed cell 
death, or internal suicide) in response to intrinsic or extrinsic signals, is important to 
maintain homeostasis of an organism. Abnormal apoptosis in smooth muscle cells 
may lead to disruption of normal tissue integrity and cause venous wall changes 
and dilatation in varicose vein pathogenesis (Ascher, Jacob et al. 2000, Ducasse, 
Giannakakis et al. 2005). 
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1.4. Classification  
The CEAP (Clinical-aEtiology-Anatomy-Pathophysiology) classification was 
developed in 1994 by an international ad hoc committee of the American Venous 
Forum, and endorsed by the Society for Vascular Surgery. It was incorporated into 
the Reporting Standards in Venous Disease in 1995. The aim was to achieve 
uniformity in reports of management of venous diseases, as well as correctly 
diagnose, and systemically guide the daily clinical investigation, decision making 
and appropriate management of patients with venous disorders (Beebe, Bergan et 
al. 1996). The basic CEAP classification was refined in 2004 to include the division 
of C4 into 2 subclasses to reflect the severity of disease and risk for ulcer 
development; the introduction of a descriptor “n” for E, A, and P classification, 
where no venous abnormality is identified (Eklof, Rutherford et al. 2004). The 
CEAP classification is summarised below: 
Clinical classification (C0-6)  
C0 No visible or palpable signs of venous disease 
C1 Telangiectasies or reticular veins 
C2 Varicose veins 
C3 Edema without skin changes 
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C4 Skin and subcutaneous tissue changes ascribed to venous disease  
C4a Pigmentation or eczema  
C4b Lipodermatosclerosis or atrophie blanche  
C5 Skin changes as above, with healed ulceration 
C6 Skin changes as above, with active ulceration 
Each limb is further characterised as asymptomatic (A), or symptomatic (S). The 
higher clinical classes have more severe signs, and may also have features of a 
less severe class.  
aEtiologic classification  
Ec Congenital 
Ep Primary 
Es Secondary  
En No venous cause identified 
Venous dysfunction may be congenital (c), primary (p), or secondary. Congenital 
disorders are present at birth, but may not be diagnosed until later. Primary venous 
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dysfunction is of unknown cause (not congenital), while secondary dysfunction 
results from an acquired condition such as deep venous thrombosis. 
Anatomic classification  
As Superficial veins 
Ap Perforator veins 
Ad Deep veins 
An No venous location identified 
Multiple venous systems may be involved, in any combination.  
Pathophysiologic classification 
Pr Reflux 
Po Obstruction 
Pr,o Reflux and obstruction 
Pn No venous pathophysiology identified 
The severity of venous dysfunction is influenced by the anatomic location of any 
reflux or obstruction (Porter and Moneta 1995). The advanced CEAP therefore 
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includes the details of any of 18 anatomic segments, used for locators for venous 
pathology. 
1.5. Clinical features 
The clinical presentation of varicose veins varies among patients (Teruya and 
Ballard 2004). Patients may be asymptomatic apart from the appearance of the 
varicosities, but in general, patients fall into 2 groups with regards to clinical 
presentation: those without complications, and those with complications.  
Patients without complications may report localised symptoms such as pain, 
burning or itching, or more generalised symptoms such as aching legs, leg swelling 
or fatigue, heaviness, tingling, or restless legs (Jones and Carek 2008). These 
symptoms which are due to venous hypertension tend to be worse at the end of 
the day, especially after prolonged standing, and usually are resolved by walking, 
or sitting with leg elevation (Jones and Carek 2008). Patients who develop 
complications may present with skin pigmentation, varicose eczema, superficial 
thrombophlebitis, venous ulceration, haemorrhage and lipodermtosclerosis (Jones 
and Carek 2008).  
The relationship between symptoms and severity of venous reflux is inconsistent. 
Also, many of these symptoms may be present in people with no clinical evidence 
of varicose veins (Bradbury, Evans et al. 1999). In men, although the most 
common symptom was cramps, the Edinburgh vein study found only itching to be 
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significantly associated with trunk varices. Women were more likely to report a 
wide range of leg symptoms, and although showed significant association between 
symptoms and presence of trunk varices, the clinical significance of this is doubtful. 
Frequency of symptoms of both uncomplicated and complicated varicose veins 
increases linearly with age in both sexes (Bradbury, Evans et al. 1999, Chiesa, 
Marone et al. 2007).  
Because varicose veins rarely cause acute life threatening complications, they 
have long been given low clinical priority, and regarded as a cosmetic nuisance 
(Campbell 2006). However, varicose veins have a significant impact on quality of 
life (QoL), and several studies have consistently shown that successful treatment 
of varicose veins is associated with significant QoL benefits (Smith, Garratt et al. 
1999, Mekako, Hatfield et al. 2006, Carradice, Mekako et al. 2011).  
1.6 Assessment and investigations  
The assessment of patients with varicose veins is aimed at determining if the 
symptoms are due to venous disease, detect any complications, and detects other 
significant pathology. It has been estimated that up to a third of patients presenting 
with varicose veins, have symptoms unrelated to varicose veins, and may be 
worried about deterioration / complications (London and Nash 2000). The history 
attempts to elucidate previous DVT, leg fractures, previous venous surgery and a 
family history of varicose veins. Physical examination usually includes abdominal 
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examination to detect any scars, dilated collaterals, and any abdomino-pelvic 
cause of the varicosities.  
Limb examination is important, and is performed with patient in the erect position. It 
aims to determine the distribution of the varicosities, in particular, whether they 
arise from the GSV or SSV. The examination also includes a record of any 
complications such as skin changes, lipodermatosclerosis and ulceration. The 
performance of clinical tests such as tourniquet (Perthes and Trendelenburg), tap, 
and cough tests to define the source of reflux, are usually inaccurate, only variably 
helpful, and have largely been replaced by the use of hand held continuous wave 
doppler (Campbell, Niblett et al. 1997, Kim, Richards et al. 2000).  
Imaging studies are usually performed as part of the assessment of patients with 
varicose veins. Colour flow duplex ultrasound scan has largely replaced 
phlebography as the gold standard imaging modality for venous disease (Neglen 
and Raju 1992, Baker, Burnand et al. 1993, Cavezzi, Labropoulos et al. 2007). The 
use of duplex scanning should prevent inappropriate and / or incomplete operation 
(Mercer, Scott et al. 1998, Wills, Moylan et al. 1998), although another study by 
Kent and Weston (Kent and Weston 1998) showed that detailed clinical evaluation 
using hand held doppler resulted in appropriate surgery in 94% of patients with 
primary varicose veins. With limited resources and pressures on vascular 
laboratories and radiology units, duplex scanning is indicated in recurrent varicose 
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veins, suspected SSV incompetence, presence of complications, and in patients 
with history of DVT (Wolf and Brittenden 2001). This policy is however changing, 
as many vascular surgeons now routinely scan their patients in clinic, obviating the 
need for more formal “departmental scans”. Duplex scan is useful for mapping 
reflux within the saphenous systems, detecting SSV disease, locating SPJ and 
incompetent non-junctional perforators, as well as evaluating the deep venous 
system. In this era of increasing use of endovascular technologies for the treatment 
of varicose veins, it is becoming almost routine for vascular surgeons to perform 
duplex scanning (Bachoo 2009). Blomgren et al showed that the use of 
preoperative duplex scan resulted in changes to the planned surgery, and more 
importantly, resulted in less residual and recurrent varices at 2 years   (Blomgren, 
Johansson et al. 2005). Magnetic resonance venography is not routinely used in 
varicose veins, but remains the most sensitive and specific non invasive test for 
anatomic obstruction (Koizumi, Horie et al. 2007). 
Other investigations such as varicography (venography) and plethysmography 
have largely been replaced by duplex ultrasound scan, and rarely used in day to 
day usual clinical practice (Gloviczki, Comerota et al. 2011). 
1.7. Treatment of varicose veins and post intervention outcomes 
The optimum management of varicose veins requires accurate identification of the 
source of venous incompetence (Beale and Gough 2005). It is important to realize 
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that not all patients need to be treated, and for some patients with uncomplicated 
varicose veins, reassurance and explanation is all that is required (London and 
Nash 2000). When it is decided to treat a patient, the most appropriate treatment 
for each patient has to be decided. This decision is based on the patient’s 
symptoms, pattern and extent of reflux, presence of co-morbidities / fitness of 
patient, patient expectations, and of course skill of the surgeon and availability of 
treatment modalities. A brief overview of treatment options and summary of 
evidence for them is presented below. 
 
Compression hosiery 
The use of compression stockings can relieve symptoms, improve venous 
haemodynamics, and prevent deterioration of skin changes associated with venous 
hypertension (Ibegbuna, Delis et al. 1997, Zajkowski, Proctor et al. 2002). 
Compression acts by providing graduated radial pressure between the ankle and 
the knee or thigh. The maximal pressure is exerted at the ankle, and reduces to 
75% at the calf, and 50% at the thigh (Sam and Bradbury 2007). The compression 
combined with the action of the calf muscle pump facilitates cephalad blood flow 
and venous return (Somerville, Brow et al. 1974). Compression is usually most 
effective at an ankle pressure of 20 - 30 mmHg (class 2), (Hirai, Iwata et al. 2002), 
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but class 1 (15 - 20 mmHg) and class 3 (30 - 40 mmHg) compression are also 
utilised. The effect of compression is limited to the period during which it is worn, 
and the tolerance and compliance by patients is variable (Beale and Gough 2005). 
Compression is often used as first line treatment in the community, and can be 
used as primary treatment for some patients who are otherwise not candidates for 
any interventional therapy. Compression is also used as an adjunct to invasive 
management, for variable lengths of time. The ESCHAR trial showed good 
evidence for the efficacy of compression after varicose vein surgery in the 
reduction of ulcer recurrence (Gohel, Barwell et al. 2007). The efficacy of 
compression stockings for primary management of varicose veins is limited. In the 
REACTIV trial for example, Michaels and colleagues found that over half of their 
patients randomised to conservative management of their varicose veins with 
compression, expressed unhappiness with their treatment, and crossed over to 
have surgery (Michaels, Campbell et al. 2006). Again, Anderson et al found no 
significant difference between placebo plus stockings versus placebo alone, in 
terms of scores for symptoms of pain, heaviness, itching, swelling, night cramps 
and cosmetic appearance, although the study may have lacked power to detect 
clinically significant changes (Anderson, Geraghty et al. 1990). There are however, 
reports of marked improvement in pain, swelling, skin pigmentation, activity and 
wellbeing, after the use of compression at 30 to 40mmHg in compliant patients 
(Motykie, Caprini et al. 1999).  
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There are no reported complications associated with the appropriate use of 
compression hosiery, apart from reported difficulty with getting them on, cost, etc, 
which may affect compliance (Beale and Gough 2005). Skin breakdown and frank 
necrosis have been reported after incorrectly measured or applied compression 
garments (Callam, Ruckley et al. 1987).   
Sclerotherapy    
Sclerotherapy, which involves the injection of a sclerosant into a vein, was made 
popular by the work of Henry and Fegan in the early 1970s (Henry, Fegan et al. 
1971). Sclerotherapy works by causing a chemical thrombophlebitis, occlusion and 
eventual fibrosis (Kern 2002). Three categories of sclerosants are in use: detergent 
solutions (sodium tetradecyl sulphate [STD] and polidocanol), osmotic solutions 
(eg hypertonic saline), and chemical irritants / corrosive agents (eg glycerine). 
Polidocanol is popular in Germany and many European countries, whereas in the 
UK, France and USA, STD is more widely used (Stucker, Kobus et al. 2010). Some 
of the documented variables which may affect the efficacy of sclerotherapy include: 
type of sclerosant (but, RCT showed no significant difference between STD and 
polidocanol; (Goldman 2002); physical state (foam or liquid) of sclerosant used 
(foam more effective than liquid; (Ouvry, Allaert et al. 2008, Rabe, Otto et al. 2008); 
and concentration of sclerosant used (higher concentration more effective; 
(Ceulen, Bullens-Goessens et al. 2007).  
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Sclerotherapy is more effective than conservative therapy or compression alone in 
reducing aching and improving cosmesis, but not for heaviness and itching and 
swelling (Michaels, Campbell et al. 2006, Tisi 2007). Old studies (Rutgers and 
Kitslaar 1994, Dwerryhouse, Davies et al. 1999) have shown superiority of 
conventional surgery over sclerotherapy in terms of venous and clinical reflux. The 
ongoing recently commissioned, nationwide Comparision of LAser Surgery and 
foam Sclerotherpy (CLASS) Trial should hopefully answer the question of 
camparison of these modalities for the management of primary varicose veins. A 
recently published trial by Rasmussen et al, akin to the CLASS trial, randomised 
500 patients to receiving one of EVLA, radiofrequency ablation, foam 
sclerotherapy, and surgery. At 1 year, significantly more GSVs were refluxing in the 
foam sclerotherapy group than in any other group (Rasmussen, Lawaetz et al. 
2011). At present, outside of the CLASS and other trials, sclerotherapy is most 
often used as an adjunct to other modes of management of varicose veins (Tisi 
2007).  
Complications and adverse events following sclerotherapy can be grouped as 
neurosensorial deficits (visual disturbances, headaches, migraines, Transient 
Ischaemic attacks and strokes), thrombotic complications (DVTs, superficial 
thrombophlebitis, PEs), general complications (allergy, anaphylaxis, infection, 
chest tightness), and local complications (hyper pigmentation, intra arterial / extra-
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venous injection, skin ulceration and necrosis, nerve injury). These complications 
occur with variable frequency depending on a number of factors including technical 
skills, type, nature, concentration, and volume of sclerosant used; overall however, 
they are estimated to occur at a rate of 0.22% per session with liquid, and 0.58% 
per session with foam (Guex, Allaert et al. 2005).  
Endovascular therapies 
In recent years there has been an endovascular revolution, resulting in the 
emergence of minimally invasive options for the management of varicose veins. 
The main front runners in this revolution are endovenous laser ablation (EVLA) and 
radiofrequency ablation (Stirling and Shortell 2006, Carradice, Mekako et al. 2011). 
Vein ablation is achieved by different technologies, but the principle and 
mechanism of action is similar, in the fact that thermal damage is done to the vein 
wall, with subsequent sclerosis and disappearance of the vein, as healing and re-
absorption take place (Bachoo 2009). This current work did not use radiofrequency 
ablation; therefore the focus will be on endovenous laser ablation, although a brief 
overview is given of radiofrequency ablation. 
Endovenous delivery of laser energy was first reported in 1999 (Bone 1999), and 
endovenous laser ablation of the GSV achieved 2 years later (Navarro, Min et al. 
2001). One major advantage of EVLA is that it is performed under local 
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anaesthesia, as an outpatient procedure. The details of the procedure will be given 
later in the methodology section, but in brief, a laser fibre is inserted under 
ultrasound guidance into the GSV or SSV and advanced to the SFJ / SPJ. 
Perivenous tumescent local anaesthetic is then infiltrated along the length of the 
vein to be ablated. Tumescent anaesthetic fluid provides pain relief, acts as a heat 
sink to absorb heat and protect surrounding tissues, as well as increase vein wall 
contact with the laser fibre, by compression (Min and Khilnani 2005, van den Bos, 
Kockaert et al. 2008). The laser fibre is then withdrawn at a speed of 1 – 3 mm per 
second, as it is fired. Compression bandaging is then applied for variable periods. 
At the time this work was done, EVLA was a staged procedure, with initial ablation 
followed in 6 – 12 weeks by outpatient sclerotherapy in up to 90% of cases (Beale 
and Gough 2005).   
The exact mechanism by which EVLA causes damage to the vein wall is still 
unclear, though various mechanisms have been proposed. Heat damage to the 
vein wall, either directly from the hot laser fibre tip (reaching temperatures of 
between 800 and 1300 degrees Celcius), or the effect of boiling blood bubbles, 
which transfer heat from the fibre tip to the vein walls, where they condense and 
dissipate the heat energy, appear to be the most likely mechanisms (van den Bos, 
Kockaert et al. 2008, van den Bos, Kockaert et al. 2009). 
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Various laser modalities and energy deliveries have been used, but 810 nm diode 
delivering power at 10 – 14 Watts has been most widely used (Beale and Gough 
2005). A recent study by Vuylseteke et al compared 1500nm and 980nm diode 
laser in EVLA of GSV varicosities. They found similar occlusion rates, but the 
higher wavelength delivery was associated with less post procedure induration 
(Vuylsteke, De Bo et al. 2011). Other studies have shown similar findings of 
equivalent efficacy, but less adverse effects with the longer wavelengths laser light 
(Proebstle, Moehler et al. 2005, Kabnick 2006). The clinical and QoL efficacy of 
EVLA has been demonstrated by several studies, with reported immediate and 
short-term GSV closure rates of 94% - 100%, and at least 90% after 3 years  
(Beale and Gough 2005, Min and Khilnani 2005, Carradice, Mekako et al. 2011). 
Both generic and disease specific QoL are significantly improved by EVLA of 
truncal varicosities in the short and medium term (Rasmussen, Bjoern et al. 2010, 
Carradice, Mekako et al. 2011).  
Reported complications following EVLA include bruising, thrombophlebitis, hyper 
pigmentation, skin burns, paraesthesia and DVT (Mundy, Merlin et al. 2005, 
Mekako and Chetter 2007).  
Radiofrequency ablation (RFA) was introduced in 1999 with early reports 
appearing in 2000 (Gloviczki, Comerota et al. 2011). The procedure is similar to 
EVLA, in respect of ultrasound guided introduction of catheter into the varicose 
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vein, use of tumescent anaesthetic and catheter withdrawal during treatment. RFA 
however utilises a different modality for endovenous thermal delivery. The 
introduction of the ClosureFast® catheter which has a 7cm area of heating in the 
probe, improved the speed of treatment delivery, and the efficacy of RFA (Health 
Quality 2011). Complications and efficacy are similar to EVLA, especially with the 
2nd generation catheters, although there may be less bruising and possibly higher 
rates of DVT with RFA as compared with EVLA (Gloviczki, Comerota et al. 2011, 
Health Quality 2011).  
Surgery 
Standard surgery for varicose veins dates back over a century, when Babcock 
described a ‘new procedure for the extirpation of varicose veins of the leg’ 
(Babcock 1907). Surgery has since been regarded as the gold standard for 
treatment of varicose veins, and the yard-stick against which more recent 
treatment forms are compared. Surgery for varicose veins is one of the most 
common interventions performed in the UK and most of the Western World 
(Department of Health 2005).  
Various surgical techniques and options have been described and utilized in the 
management of both primary and recurrent varicose veins. For varicosities of the 
GSV, which are by far the most common, the evidence based surgical 
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recommendation is for patients to undergo a high tie (sapheno-femoral junction 
ligation), with stripping of the GSV to about one hand’s breadth below the knee, 
and phlebectomies (multiple stab avulsions) of tributary varicosities (Beale and 
Gough 2005). Surgery is usually performed as a day-case procedure, under a 
general anaesthetic. The detailed surgical procedure will be described later in the 
methods section, but briefly, it entails making a groin-crease incision, identifying 
the SFJ and ligating this, after ligation and division of the main tributaries of the 
GSV at or close to the SFJ. These tributaries should be ligated and divided beyond 
their secondary branch points to reduce the risk of reconnection and subsequent 
recurrence. The GSV is then stripped, preferably using a PIN (perforator 
invagination) stripper, which causes inversion of the vein as it is being stripped. 
Inversion stripping is believed to reduce bleeding and minimize the chances of 
nerve damage, although this was not proved by previous RCTs (Durkin, Turton et 
al. 1999, Lacroix, Nevelsteen et al. 1999). Tributary varicosities are then avulsed 
through multiple stab incisions, using vein hooks or kocherised mosquito forceps. 
Post operatively, compression is applied by bandaging or stockings for a variable 
length of time.  
Various modifications of the above procedure have been (and still being) used in 
an attempt to deal with the GSV, improve results, and reduce complications. These 
include: the use of tourniquet to reduce blood loss (Sykes, Brookes et al. 2000); 
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cryostripping, which has similar clinical and QoL outcomes as standard stripping, 
but causes less bruising (Menyhei, Gyevnar et al. 2008); transilluminated powered 
phlebectomy, which requires less incisions for phlebectomies, but associated with 
significantly more bruising, prolonged pain and poor early postoperative QoL as 
compared with hook avulsions (Chetter, Mylankal et al. 2006). Sapheno-femoral 
junction ligation has also been combined with foam sclerotherapy or EVLA of the 
GSV. Other surgical procedures such as ambulatory conservative haemodynamic 
management (CHIVA), perforator surgery, and external valvular cuffs / stents exist, 
but are not described in this work. 
Complications associated with varicose vein surgery include bleeding (which may 
include major injuries to the femoral vessels), haematoma and wound 
complications including infection can occur in up to 10% of cases (Corder, 
Schache et al. 1991, Mekako, Chetter et al. 2010), nerve injuries, which may range 
from paraesthesia, to foot drop, and venous thrombo embolism. Recurrence rates 
after surgery vary depending on definition, initial procedure performed, mode of 
identification, and length of follow up (Beale and Gough 2005). Quoted rates of 
recurrence range from 7% - 70% (Winterborn, Foy et al. 2004), although following 
surgery with GSV stripping, the rates of clinical recurrence are between 25% and 
37% (Munn, Morton et al. 1981, Dwerryhouse, Davies et al. 1999). Overall, about 
20% of varicose vein surgeries are performed for recurrent disease (Bradbury, 
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Stonebridge et al. 1993). It would be anticipated that in the era of endovenous 
therapies, this proportion would reduce.  
Surgery has been shown to be effective in relieving symptoms, and improving QoL 
(Mackenzie, Lee et al. 2002, MacKenzie, Paisley et al. 2002, Carradice, Mekako et 
al. 2011). Wound infection following varicose vein surgery can be a significant 
limitation to the delivery of effective surgical intervention. Surgical site infections 
and the use of prophylactic antibiotics in varicose vein surgery are now explored 
further. 
Surgical site infections (SSIs) and use of antibiotic prophylaxis in varicose vein 
surgery 
The rate of groin wound infection following varicose vein surgery may reach 16% 
(Corder, Schache et al. 1991, Hayden and Holdsworth 2001, Hirsemann, Sohr et 
al. 2005). SSIs are the commonest of hospital acquired infections among surgical 
patients in the UK, affecting up to 10% of patients. In the USA, this proportion 
reaches up to 38% (Mangram AJ, Horan TC et al. 1999, Nosocmial Infection 
National Surveillance Service 2001). When patients develop an SSI following 
varicose vein surgery, it is usually a superficial incisional infection, the 
characteristics of which must meet the following Centres for Disease Control and 
Prevention (CDC) definition criteria (Horan, Andrus et al. 2008): 
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Infection occurs within 30 days after the operative procedure and involves only skin 
and subcutaneous tissue of the incision, and patient has at least 1 of the following: 
Purulent drainage from the superficial incision 
Organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision 
At least 1 of the following signs or symptoms of infection: pain or tenderness, 
localized swelling, redness, or heat, and superficial incision is deliberately opened 
by surgeon and is culture positive or not cultured. A culture-negative finding does 
not meet this criterion. 
Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
The CDC definition is only one of several definitions for wound infection used in 
published studies. There are several other definitions for identification and 
surveillance of SSIs, including scoring systems like the ASEPSIS method, which 
was designed for use in clinical trials of antibiotic prophylaxis (Wilson, Treasure et 
al. 1986). The ASEPSIS method was used in this study and more details will be 
given in the methods section. 
  
67 
 
SSIs are a significant problem which limits the potential benefits of surgical 
interventions. The impact on hospital costs and postoperative length of stay is 
considerable. 
The use of antibiotics to prevent SSIs has long been established (Mangram, Horan 
et al. 1999). In vascular surgery, although antibiotics have been shown to be 
effective in preventing SSI in arterial bypass surgery (Turtiainen, Saimanen et al. 
2010), no similar studies have previously looked specifically at their use in varicose 
vein surgery.  
What outcomes are important in the treatment of varicose veins? 
The aim of any form of intervention in patient care whenever possible is to 
eradicate the problem / control the symptoms and preserve or restore quality of life, 
with minimal complications (Tisi 2007). Outcome assessment of therapy for 
varicose veins includes standardised objective criteria that reflect patient 
symptoms, characteristic signs, and objective measures of functional and disease 
specific quality of life (Gloviczki, Comerota et al. 2011). Varicose veins cause 
cosmetic concerns, symptoms and complications, and also affect quality of life. 
The optimal management of varicose veins must therefore address these problems 
and take patient expectations into account. In a study investigating patient 
preferences and expectations in varicose vein treatment, Shepherd et al 
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(Shepherd, Gohel et al. 2010) found that although only half of 111 patients knew of 
endovascular ablative therapies, the majority of patients would prefer a local 
anaesthetic procedure for their varicose vein treatment. The majority of their 
patients (80%) would however be influenced in their choice of treatment, by their 
surgeon. This would indicate that to a large extent, the surgeon is in the driving 
seat with regards to optimal management for each patient. On the basis of current 
evidence, it would appear that the minimally invasive therapies especially EVLA 
offer an ideal management for varicose veins, with excellent efficacy, minimal side 
effects / complications, and preservation of quality of life. Not all varicose veins are 
however suitable for these minimally invasive therapies and a significant proportion 
of patients who undergo EVLA would require subsequent adjunctive procedures. It 
therefore means that surgery remains an important option for management. 
Surgery, as has been previously highlighted, although very effective, has 
significant complications, especially wound complications.  
It would therefore be likely that the optimal treatment for varicose veins is not a one 
cap fits all modality, and that several factors are taken into reckoning. Since it is 
the objective of intervention to eradicate varicose veins, eliminate symptoms, and 
preserve quality of life, the “ideal” mode of therapy may well be patient and 
varicosity specific, and involve a combination of techniques. 
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2. AIMS  
Since the introduction of varicose vein surgery by Babcock over a century ago, 
treatment of varicose veins has undergone modification and modernisation with the 
objective of improving efficacy and minimising complications. Analysis of quality of 
life outcomes has now become common place in assessing the impact of 
interventions. Indeed this is now recommended in analysis of outcomes of 
intervention for varicose veins (van Korlaar, Vossen et al. 2003). In the last 
decade, the minimally invasive therapies have undergone a revolution, with 
expansion of indications and applicability. There is therefore the need to explore 
the available treatment options with the aim of optimising the management of 
varicose veins. 
Important questions to address in the optimal management of varicose veins would 
include: 
What proportion of patients with varicose veins can undergo EVLA? 
How can EVLA be optimised for efficacy, reduce the need for subsequent 
procedure, and yet preserve the excellent patient experience? 
How does EVLA compare with surgery? 
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Can the use of prophylactic antibiotics reduce wound complications following 
surgery for varicose veins? 
These and other issues are the focus of this present work. This work does not 
focus on the use of foam sclerotherapy or other forms of endovenous therapies 
besides laser ablation. 
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3. METHODS 
To address the various issues to be dealt with in this present work, 4 studies were 
performed: 
Study 1 
What proportion of patients with varicose veins is suitable for endovenous laser 
ablation? 
Study 2 
Combined endovenous therapy and ambulatory phlebectomy: refinement of a new 
technique (Eur J Vasc Endovasc Surg 2006; 32(6); 725 - 729) 
Study 3 
A non randomized controlled trial of endovenous laser therapy and surgery in the 
treatment of varicose veins (Ann Vasc Surg 2006; 20(4): 451 - 457) 
Study 4 
Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in 
varicose vein surgery (Br J Surg 2010; 97(1): 29 - 36)  
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3.1. STUDY 1  
AN ANALYSIS OF THE SUITABILITY FOR ENDOVENOUS 
ABLATION IN PATIENTS WITH LOWER LIMB VARICOSE 
VEINS 
The introduction of minimally invasive treatment for varicose veins brought the 
appeal of combining efficacy with minimal negative impact on QoL. As with any 
new technology, there was caution mixed with optimism and guarded indications. 
In the first year of introduction of EVLA in our centre, we aimed to see what 
proportion of patients with varicose veins could undergo laser ablation of their 
varicosities.  
Study Design 
 This study was designed as a prospective observational series 
Recruitment 
Over a 12 month period beginning June 2004, a random selection of patients on a 
waiting list for varicose vein surgery was invited to attend for a duplex scan to 
assess their suitability for endovenous ablation.  
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All patients listed for unilateral primary SFJ ligation (high tie), stripping of the great 
saphenous vein, and multiple stab avulsions (phlebectomies) were identified. This 
formed the primary inclusion criterion. A random sample of these patients was then 
generated, and the selected patients were invited to attend the vascular laboratory 
for duplex ultrasound scan. Suitability criteria for laser ablation were devised, using 
the best available evidence on EVLA in the then current literature. These criteria 
were suggested in order to limit the incidence of technical and clinical failure of the 
procedure. 
Suitability Criteria  
The following suitability criteria were employed:  
Isolated SFJ incompetence and/or GSV reflux 
Absence of incompetent major antero-lateral (anterior accessory GSV) thigh 
branch terminating within 2cm of the SFJ  
Absence of duplicated GSV  
Perigenicular GSV diameters greater than 5mm 
Patient acceptance of local anaesthetic procedure 
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Duplex scanning  
Scanning was performed using a SonoSite Titan® machine (SonoSite Inc. Bothell, 
WA) with a 5 –10 MHz 38mm broadband linear array probe. All limbs were 
scanned in the upright position, with the limb externally rotated, and the weight 
taken on the contra lateral limb. The superficial and deep veins, including junctions 
and perforators were examined. Duplex scanning was carried out in B and colour 
Doppler modes. Antegrade and retrograde flow was examined by a distal 
compression-release technique, augmented with the valsalva manoeuvre. Reflux 
was regarded as a retrograde flow of >0.5 seconds on pulsed-wave Doppler, as 
previously defined for superficial veins of the lower limb (Labropoulos, Tiongson et 
al. 2003). All scans were performed by a vascular ultrasound scientist and 
corroborated by a vascular surgeon trained in vascular ultrasound. Data was 
entered prospectively into a specially designed database.  
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3.2. STUDY 2  
AN ANALYSIS OF THE FEASIBILITY AND ACCEPTABILITY 
OF EVLA AND AMBULATORY PHLEBECTOMY IN 
PATIENTS WITH LOWER LIMB VARICOSE VEINS 
EVLA is effective in eradicating reflux in the treated vein. It is generally performed 
under local tumescent anaesthesia and is associated with very good patient 
tolerability, acceptance and satisfaction. As treatment was traditionally limited to 
the truncal vein, 30% - 99% of patients required secondary treatment of residual 
varicosities, usually in the form of compression sclerotherapy (Beale, Mavor et al. 
2004). The need for subsequent secondary therapy means patients often require 
repeated visits to the treatment centre, as well as face associated potential 
complications of sclerotherapy; this may be a relative limitation to the otherwise 
high patient acceptability of endovenous laser therapy.  
This study aimed to assess if combining EVLT and ambulatory phlebectomy as a 
single procedure (a combination procedure were have called EVLTAP), was 
feasible, effective and acceptable to patients. 
Study Design 
This study was designed as a prospective observational series 
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Recruitment  
Patients were selected by screening the day-case varicose veins waiting list, and 
inviting patients listed for high tie, GSV stripping and avulsions for duplex scan 
(see details in study 1). Patients, who matched the local suitability criteria as 
previously detailed, were offered EVLTAP. Patients with short saphenous 
varicosities, anterolateral thigh branch incompetence, previous varicose vein 
surgery and GSV with a diameter of less than 5mm at the knee were excluded.  
All patients signed an informed consent form before undergoing EVLTAP. The 
study was approved by the Hull and East Riding Local Research Ethics Committee 
and carried out in accordance with the Helsinki Declaration. 
Technique Description 
All procedures commenced with laser ablation of the incompetent GSV. The SFJ 
was identified by duplex ultrasound scan (DUS) in the upright position and the 
course of the GSV followed down to the knee, with intermittent skin markings. The 
patient was positioned in the reverse trendelenburg position and skin preparation 
and draping carried out. The peri-genicular entry point into the GSV was again 
identified and 1-2 ml of 1% plain lignocaine infiltrated into the skin. Percutaneous 
entry into the GSV was gained, using a 19-guage needle under ultrasound 
guidance. In 2 patients where percutaneous cannulation of the GSV at the knee 
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was impossible due to small vein size (following vein wall spasm), open 
cannulation was achieved via a stab wound, and “hooking up” the vein. A 0.035-
inch diameter J guide wire was inserted through the needle, which was 
subsequently removed. A 5F catheter was introduced over the guide wire and 
positioned within the GSV, immediately distal to the SFJ. Its position was 
confirmed by ultrasound, and the aspiration of non-pulsatile blood. A sterile bare-
tipped laser fibre, 600m in diameter was introduced into the catheter to its first 
mark (which placed its tip flush with the end of the catheter). The catheter was then 
withdrawn to the second mark on the fibre, while keeping the position of the laser 
fibre fixed. This resulted in protrusion of 2 cm of the bare-tipped laser fibre beyond 
the catheter tip. The fibre was locked in the catheter in this position. The patient 
was then positioned in Trendelenburg position to aid vein emptying.  
Tumescent local anaesthetic solution was infiltrated along the whole length of the 
GSV to be ablated, using a 0.9mm X 180mm needle under ultrasound guidance. 
Tumescent anaesthetic solution was prepared by diluting 30ml of 2% lignocaine 
(with 1:200,000 adrenaline), in 500ml of saline). Tumescent local anaesthetic was 
also infiltrated around branch varicosities. Total local anaesthetic used in each 
case, did not exceed recommended maximum safe dose of 7mg/kg per patient.  
Laser energy was delivered endovenously using an 810 nm diode laser generator 
(Diomed Ltd, Cambridge, United Kingdom). 12 or 14 W power in pulsed or 
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continuous mode was utilised. During the laser ablation process, manual 
compression was applied to the limb over the tip of the laser fibre to aid vein wall 
apposition and improve heat conduction.  
Following laser ablation of the GSV from groin to knee, stab incisions of 1- 2 mm 
were made over varicosities, which were then avulsed using kocherised mosquito 
artery forceps or Mueller hooks as conventionally done. Steri-strips and gauze 
dressings were applied to stab wounds.  
Panelast®  (Lohmann & Rauscher International GmbH & Co. KG) elastic adhesive 
bandage was applied to the whole length of the treated limb post procedure and 
left in place until the first follow up at 1 week, when it was changed to a class II (30-
40mmHg) full-length graduated support stocking that was worn for a further 5 
weeks, except during sleep and baths. All patients were asked to walk immediately 
after the procedure, and to return to normal activities as soon as they felt 
comfortable. A 1-week course of non-steroidal anti-inflammatory drugs was 
prescribed for all patients with no contraindication to their use. 
Postoperative Assessments and Outcome Measures 
Pain  
Pain was assessed on days 1, 4 and 7 using a visual analogue scale (VAS) rating 
of 0cm (no pain) to 10cm (worst imaginable pain). This was entered by patients in 
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a diary given to them at the completion of the procedure. Diaries were reviewed at 
1-week follow up.  
GSV occlusion rates on Duplex Ultrasound Scan 
Duplex ultrasound scan was performed at 1 and 12 weeks post procedure to 
assess SFJ and GSV occlusion. Reflux was defined as greater than 0.5 seconds 
retrograde flow. All scans were performed by the same investigator to avoid inter 
observer variability 
Subsequent interventions  
Patients were assessed at 6 weeks, and any one who had residual varicosities was 
offered either sclerotherapy or further phlebectomies. 
Patient Satisfaction 
Patient satisfaction was assessed at 12 weeks using a VAS rating of 0cm 
(completely dissatisfied) to 10cm (completely satisfied). Patient satisfaction with 
cosmetic outcome and with overall treatment was assessed separately. The overall 
treatment satisfaction was a composite assessment that included treatment 
deliveries, length of procedure, follow up treatment and recovery. It gave an 
indication of patient acceptability of the procedure.  
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3.3. STUDY 3  
A NON RANDOMISED CONTROLLED TRIAL OF 
ENDOVENOUS AND SURGICAL TREATMENT OF 
PATIENTS WITH VARICOSE VEINS 
Surgery has been the gold standard for the treatment of varicose veins. Surgical 
treatment is effective at abolishing reflux, correcting symptoms and restoring 
quality of life (QoL) (Carradice, Mekako et al. 2011). More recently, minimally 
invasive therapies have emerged, which combine efficacy with diminished 
complication rates and high levels of acceptance. EVLA is one of the front runners 
in this endovascular revolution. It is a local anaesthetic procedure that can be 
performed on an ambulant basis, often as an office procedure. The procedure has 
impressive GSV ablation rates at up to 5 years follow up (Min and Khilnani 2005). 
Successful treatment should however not be interpreted only in the context of 
ablation rates, but also in respect of total patient well-being. Health related QoL is 
the patient-perceived functional effect of an illness and its consequent therapy. It 
has been proposed that QoL measures should be standard in studies involving 
patients with venous diseases (van Korlaar, Vossen et al. 2003).  
  
81 
 
The aim of this study was to compare early quality of life outcomes following 
surgery and EVLA in the treatment of patients with varicose veins. 
Study Design 
This trial was designed as a prospective, non-randomized, controlled observational 
study of patients undergoing endovenous and surgical treatment for lower limb 
varicose veins. We designed this study to function as a pilot study, the results of 
which would be utilized in a power calculation for a future randomized controlled 
trial with QoL measures as primary outcome. 
Two groups of patients undergoing treatment for unilateral symptomatic varicose 
veins attributable to isolated SFJ incompetence and GSV reflux on preoperative 
duplex ultrasound scan were studied.  
Patient Selection  
Immediately prior to commencement of EVLA at our institution, consecutive 
consenting patients undergoing surgery for varicose veins were recruited into the 
surgery group. When EVLA commenced, all suitable consenting patients were 
recruited into the EVLA group. 
Surgery Group 
Patients in the surgery group underwent conventional SFJ ligation, stripping of the 
GSV to knee level, and multiple stab phlebectomies under general anaesthesia. All 
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procedures were carried out in the day surgery unit and performed by a consultant 
vascular surgeon or competent Specialist Registrar. Crepe bandage compression 
was applied post op for 2 - 4 hours, after which it was changed to a class II (20 - 40 
mmHg) full-length graduated support stocking as patient was discharged. This was 
worn continuously for 1 week and then during the day for a further 4 weeks. All 
patients were encouraged to walk as much as possible and to return to normal 
activities as soon as they felt able. All patients without contraindications were 
prescribed a 1-week course of non steroidal anti-inflammatory tablets (Diclofenac 
50mg to be taken 3 times daily).    
EVLA group 
These patients underwent EVLA with concomitant multiple stab phlebectomies 
under tumescent local anaesthetic. All procedures were carried out by a single 
vascular surgeon proficient in EVLA technique, and took place in the surgical out 
patient clinic minor theatre. The SFJ was identified by duplex ultrasound scan in 
the upright position and the course of the GSV followed down to the knee, with 
intermittent skin markings. The patient was then positioned in the reverse 
Trendelenburg position and skin preparation and draping carried out. The peri-
genicular entry point into the GSV was again identified and 1-2 ml of 1% plain 
lignocaine infiltrated into the skin. Percutaneous entry into the GSV was gained, 
using a 19-guage needle under ultrasound guidance. A 0.035-inch diameter J 
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guide wire was inserted through the needle, which was subsequently removed. A 
5Fg catheter was introduced over the guide wire and correctly positioned within the 
GSV, immediately distal to the SFJ. Its position was confirmed by ultrasound. A 
sterile bare-tipped 600m laser fibre was introduced into the catheter to its first 
mark, placing its tip flush with the end of the catheter. The catheter was then 
withdrawn to the second mark on the fibre, while keeping the position of the laser 
fibre fixed. This resulted in protrusion of 2 cm of the bare-tipped laser fibre beyond 
the catheter. The fibre was locked within the catheter in this position. The patient 
was positioned in Trendelenburg position to aid vein emptying.  
Perivenous tumescent local anaesthetic (0.2% lignocaine with 1:200,000 
adrenaline) was infiltrated along the whole length of the GSV to be ablated, using a 
0.9mm x 180mm needle under ultrasound guidance. Local anaesthetic was also 
infiltrated around branch varicosities in a field block fashion. Total local anaesthetic 
did not exceed recommended maximum safe dose per patient.  
Laser energy was delivered endovenously using an 810 nm diode laser generator 
(Diomed Ltd, Cambridge, United Kingdom). 12 or 14 W power in pulsed or 
continuous mode was utilized. During the ablation process, manual compression 
was applied to limb, over the tip of the laser fibre to aid vein wall apposition and 
improve heat conduction to vein wall. Following laser ablation of the GSV from 
groin to knee, stab incisions of 1- 2 mm were made over varicose tributaries, and 
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the veins avulsed using mosquito artery forceps or Mueller hook as conventionally 
done. Steri-strips and gauze dressings were applied to stab wounds.  
Panelast®  (Lohmann & Rauscher International GmbH & Co. KG) elastic adhesive 
bandage was applied to the whole length of the treated limb post procedure and 
left in place till the first follow up at 1 week, when it was changed to a class II (20-
40mmHg) full-length graduated support stocking that was worn for a further 5 
weeks, except during sleep and baths. All patients were asked to walk immediately 
after the procedure, and to return to normal activities as soon as they felt 
comfortable. Post operative analgesic / anti-inflammatory regime was as in the 
surgery group.  
Success of EVLA was confirmed by duplex ultrasound scanning at 1 week and 12 
weeks.     
Postoperative Assessments and outcome measures 
Patients were assessed prior to intervention, and at 1 week, 6 weeks and 12 
weeks post procedure, using the medical outcomes short form 36 (SF-36) health 
survey, Aberdeen varicose veins questionnaire (AVVQ), and the venous clinical 
severity score (VCSS). 
The SF-36 is a widely used generic QoL instrument that has been demonstrated to 
be valid, reliable and sensitive (Baker, Turnbull et al. 1995). It consists of 36 
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individual items aggregated to form 8 domains: Physical Functioning (PF), Role-
Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social 
Functioning (SF), Role Emotional (RE) and Mental Health (MH). Each domain is 
scored from 0 (worst score) to 100 (best score). The 8 domains (or scales) are 
aggregated to form two distinct component summary measures – Physical and 
Mental component summary measures. Three scales (PF, RP, BP) correlate most 
highly with the physical component and contribute most to the scoring of the 
Physical Component Summary (PCS) measure. The mental component correlates 
most highly with the MH, RE, and SF scales, which also contribute most to the 
scoring of the Mental Component Summary (MCS) measure. Three of the scales 
(VT, GH, and SF) have significant correlations with both components (Ware, 
Kosinski et al. 1994). As a general QoL measurement tool, the SF-36 may be used 
to compare health status both among patients with the same condition and between 
patients with different conditions. It may also be administered to general populations 
to see how a particular condition causes deviation from normal population 
standards (Ruta, Abdalla et al. 1994). 
The AVVQ is a validated disease – specific health related QoL instrument for lower 
limb venous disease (Garratt, Macdonald et al. 1993). The questionnaire has 13 
questions which cover all aspects of varicose vein clinical presentation including 
distribution, symptomatology, complications and management (analgesia and 
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compression). It was designed in 1993, with two independent vascular surgeons 
assigning weights to the individual questions, in proportion to the perceived 
contribution to severity of the disease (or the intervention) of that particular 
question. (Garratt, Macdonald et al. 1993). It gives a single disease-specific index 
scored from 0 (no venous symptoms) to 100 (extreme venous symptoms). As a 
disease – specific instrument, the Aberdeen Questionnaire, is believed to be more 
responsive to clinically important changes in health as a result of an intervention 
than generic instruments. The VCSS, introduced by Rutherford and colleagues in 
2000, is the American Venous Forum’s modification of the clinical score of the 
Clinical-Etiologic-Anatomic-Pathophysiologic (CEAP) classification of chronic 
venous disease. It was designed to be a quantifiable measure of disease severity, 
dynamic enough to measure change in response to treatment (Rutherford, 
Padberg et al. 2000). It scores 9 clinical characteristics of chronic venous disease 
in varying grades of severity, and has been validated for severity scoring in 
varicose vein surgery (Kakkos, Rivera et al. 2003). It correlates well the CEAP 
score, as well as with ultrasound assessment of the severity of venous 
incompetence or obstruction (Gloviczki, Comerota et al. 2011). VCSS assessment 
was performed prior to, and at 12 weeks post treatment.  
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Statistical analysis 
Data was collected prospectively, and entered into a specifically designed 
database. Statistical analysis was performed with SPSS for Windows version 12 
(SPSS Inc, Chicago Ill). Mann-Whitney test was used for intergroup analysis. 
Intragroup analysis was performed using Friedman test (across all time points) and 
Wilcoxon ranked sum test (used for comparing 2 time points). Adjustment for 
baseline differences between the groups was done by an analysis of co-variance 
(ANCOVA). Results are expressed as median (interquartile range [IQR]), and p 
<0.01 was considered statistically significant. 
Ethics  
This study was approved by the Hull and East Riding Local Research Ethics 
Committee and by the Research and Development Unit of the Hull and East 
Yorkshire (NHS) Trust.  
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3.4. STUDY 4  
A RANDOMISED CONTROLLED TRIAL OF 
PROPHYLACTIC ANTIBIOTICS IN PATIENTS 
UNDERGOING SURGICAL TREATMENT OF VARICOSE 
VEINS  
Varicose vein surgery is clean surgery, and therefore has associated predicted 
wound infection rates of 1% - 5% (Garner, Jarvis et al. 1988). There is however, 
considerable variability in reported wound infection rates, ranging from 1.5% - 16% 
(Corder, Schache et al. 1991, Hayden and Holdsworth 2001, Hirsemann, Sohr et 
al. 2005). The true value of prophylactic antibiotics in clean non-implant surgery is 
unresolved, and at the time of this study, there was no level-1 evidence specifically 
examining the value of prophylactic antibiotics in varicose vein surgery. This study 
aimed to assess postoperative groin wound complications following surgery for 
varicose veins, and examined the use of prophylactic antibiotics in this situation.  
Study Design 
This study was designed as a double blind randomized controlled trial, to study the 
effect of a single-dose prophylactic antibiotic on wound-related complications 
following varicose vein surgery. Two parallel groups were compared. The 
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intervention group received co amoxiclav, while the control group received no 
medication. 
Study Population and Setting 
The study population comprised patients undergoing groin surgery for varicose 
veins. Recruitment was based on the following criteria: 
Inclusion criteria 
All patients with varicosities of the greater saphenous vein (GSV) listed for 
saphenofemoral ligation, stripping of the GSV and phlebectomies 
All patients who agreed to participate in the study and gave written informed 
consent for the same 
Exclusion criteria 
Patients whose surgery did not include a groin incision 
Patients below the age of 18 years 
Pregnant or lactating women 
Patients with penicillin allergy 
Patients receiving antibiotics for other indications 
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Setting 
This study was conducted at a single academic vascular surgical unit of a 
university hospital, the Hull Royal Infirmary, Hull, in East Riding of Yorkshire, North 
East England. Recruitment and randomization took place between May 2003 and 
December 2005. The majority of patients with varicose veins were referred to the 
hospital by their General Practitioners (GPs). A small proportion of patients were 
referred from other specialty clinics, where symptomatic varicose veins were 
identified, following consultation for other issues.  
Patients presenting to the unit with varicose veins were given preliminary 
information on the trial by the consulting surgeon, during their consultation. All 
patients who expressed an interest in participating in the trial, or who requested 
further information, were provided with the study information leaflet and their 
details passed on to the trial team. A trial team member then contacted the 
potential participants with further details and where preliminary consent was 
obtained the participants were brought to the vascular laboratory where formal 
consenting and randomization was carried out. Following the consent and 
randomization, participants received a copy of the patient diary and full explanation 
on self assessment of groin wound. Opportunity was given to participants to ask 
questions at every stage of the process. Comprehension of both wound 
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assessment and diary completion was ascertained by asking participants direct 
closed ended questions.   
At the time of recruitment and intervention, the unit had 5 consultant and 3 trainee 
vascular surgeons, with a case-load of approximately 600 varicose vein 
procedures per year. Varicose vein service at the hospital remains a predominantly 
consultant-led, day-case service. General anesthesia was administered by either a 
consultant anaesthetist, or a specialist registrar. 
Sample size 
The sample size calculation was based on the detection of a clinically significant 
reduction of wound infection rates by the administration of prophylactic antibiotics. 
Wound infection rates of 1.5% - 16% have been reported, following varicose vein 
surgery (Corder, Schache et al. 1991, Hayden and Holdsworth 2001, Hirsemann, 
Sohr et al. 2005). However, because varicose vein surgery is clean surgery, the 
expected wound infection rates should not exceed 5% (Garner, Jarvis et al. 1988). 
It was therefore estimated that a reduction in wound infection rate from 14% to 5% 
would be regarded as a clinically significant effect size.  
A proposed 80% statistical power was set, with a 2-sided significance level of 5%. 
This provided an estimated required sample size of 190 patients in each arm (Epi 
Ifo version 6 statistical software; some rounding errors assumed). An estimated 
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15% dropout or loss to follow up was made, resulting in a target recruitment of 220 
patients in each arm. 
About 80% of varicose veins will affect the greater saphenous vein system 
(Cheatle 2005). It was thus estimated that based on the varicose vein workload of 
the unit, there will be about 480 referrals with varicosity of the greater saphenous 
vein. If 50% of referred patients consented to participation in the trial, it would take 
about 2 years to recruit the required sample size. It was therefore planned to 
complete recruitment and randomization in about 2 years. 
Randomization  
To ensure appropriate balance of the groups, like in all well designed and 
conducted RCTs, randomization was carried out. It was proposed to perform 
permuted block randomization to ensure a balanced allocation of number of 
participants to each group (Beller, Gebski et al. 2002). Blocks of 50 were derived, 
using computer-generated sequences and administered using sealed opaque 
envelopes. Patients were randomly allocated to either receiving prophylactic 
antibiotic (treatment group) or no antibiotic (control group). Surgeons, investigators 
and patients were blinded to treatment allocation. 
To ensure allocation concealment, the anaesthetist, who was not part of the study 
team, opened randomization envelopes and administered the antibiotic (if the 
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patient was randomized to the treatment group), after induction of general 
anaesthesia. Envelopes were re-sealed using tamper-evident tape and filed in 
patients’ medical notes.  
Intervention 
All suitable prospective participants were given verbal and written information on 
the study. Those who agreed to participate, signed an informed study consent 
form, and were randomized according to the earlier description.  
All patients were seen preoperatively by a member of the surgical team and 
consented specifically for the surgical procedure. All tributary varicosities were also 
marked in the erect position. General anaesthesia was administered to all patients 
in the anaesthetic room, outside the operating room. Following induction of 
anaesthesia, the randomization envelope was opened, and those randomized to 
the treatment group were given 1.2 grams of co amoxiclav intravenously. Patients 
randomized to the control group received no additional medication. No member of 
the study team was aware of the randomization. An entry was made in the patients’ 
drug card and anaesthetic chart to indicate that they were participating in the trial, 
but no mention was made as to whether or not patients received antibiotic. 
The choice of co amoxiclav was according to local antibiotic prophylaxis policy for 
clean non-implant surgery for the hospital. Co amoxiclav is a penicillin - based 
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antibiotic containing a mixture of amoxicillin (as the trihydrate or as the sodium salt) 
and clavulanic acid (as potassium clavulanate). 1.2 grams of co amoxiclav contains 
1000mg of amoxicillin and 200mg of clavulanic acid in powder form for 
reconstitution (BNF57 2009). 
Hair removal when necessary, was done in the operating room using electric 
clipper, immediately before skin preparation, to reduce chances of wound infection 
(Tanner, Woodings et al. 2006). Skin preparation was done using neat 10% 
povidone-iodine solution.  
All patients underwent standard sapneno-femoral junction (SFJ) ligation, stripping 
of the greater saphenous vein (GSV) and stab avulsion of surface tributary 
varicosities. The procedure has been described previously, but briefly involves 
dissecting the SFJ via a transverse groin crease incision, and division of all 
tributaries after their first division. The GSV was then flush ligated and divided at 
the SFJ, and the GSV was stripped to the knee using a PIN stripper. Surface 
varicosities were then avulsed using a Kocherised mosquito clip or vein hook via 
stab incisions. All groin wounds were infiltrated with bupivacaine local anaesthetic, 
and closed with subcuticular absorbable monofilament suture, with the application 
of transparent OpsiteTM (Smith &Nephew, Hull, England) dressing. Stab incisions 
were closed with Steri-strips™ (3M, MN, USA), cotton wool, gauze and elastic 
compression dressings applied. This was later replaced by a thigh length TED™ 
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anti-embolism stocking (Tyco Healthcare, Gosport, UK), which patients were 
advised to wear for a total of 6 weeks. All patients were discharged with Diclofenac 
50mg tds to be taken regularly for 1 week and Paracetamol 1g qds for 
breakthrough pain. Patients were discharged with a planned follow up at 2 weeks 
post operatively. 
Postoperative assessment and follow up 
All patients were given a specifically designed diary for the recording of groin 
wound characteristics. Explanation and instructions on diary completion, previously 
given to all patients at randomisation and consent stage, were reiterated prior to 
discharge. Wound erythema, discharge of serous or purulent exudates and 
separation of wound edges were recorded on days 3, 5, 7, 9 and 10. These 
characteristics were based on the ASEPSIS wound scoring method, which was 
developed for use in trials of antibiotic prophylaxis (Wilson, Treasure et al. 1986). 
The ASEPSIS was developed in the mid 1980’s and first used in cardiac surgery to 
assess infection in sternotomy and vein harvest wounds. This wound scoring 
system awards weighted scores for 7 components (4 wound parameters and 3 
related criteria) of a wound infection. These are: the use of Additional treatment 
(antibiotics, incision and drainage of abscess, or wound debridement); discharge of 
Serous exudates; wound Erythema; discharge of Purulent exudates; Separation of 
tissues; Isolation of bacteria; prolongation of Stay in hospital for wound problems. 
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Wound parameters of discharge of serous exudates, erythema, discharge of 
purulent exudates, and separation of tissues were assessed and scored on each 
day of assessment. Additional treatment, isolation of bacteria and prolongation of 
hospital stay were assessed and scored once during the period of the study.  
It was necessary to make some adaptations to the scoring method to facilitate its 
use in day case setting. These included the use of patient-completed 
questionnaires / diaries for wound assessment, a method previously shown to be 
reliable and valid (Mitchell, Swift et al. 1999). Other adaptations included: 
Fixed assessment time points – In the original ASEPSIS method, the 4 wound 
parameters were assessed and scored on 5 of the first 7 post op days (although 
some observations were made on day 10, when a weekend intervened, as no 
observations were made on weekends). In this study, patients assessed their 
wounds on 5 prescribed time points in the first 10 post op days (days 3, 5, 7, 9, & 
10), recoding details in a wound diary which contained specific closed questions. 
Scoring method – The original ASEPSIS awarded scores according to the 
proportion of the wound affected by each parameter, such that the presence of 
purulent exudates on any day for example, was awarded a score of 0, 2, 4, 6, 8, or 
10, if 0%, <20%, 20% - 39%, 40% - 59%, 60% - 79%, or >80% respectively, of the 
wound was affected. It was decided at the design stage, not to rely on patients to 
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give a valid quantitative assessment of proportions of wound affected, so a fixed 
score was awarded for the presence of each of the wound features. Therefore, on 
any day of assessment, the presence of purulent exudates, the presence of serous 
exudates, erythema, or separation of wound edges, was awarded a score of 6, 3, 
3, or 6 respectively. These are equivalent to the scores awarded by the original 
ASEPSIS, if 40% - 59% of the wound was affected. Although this adaptation may 
slightly reduce the responsiveness of the scoring system, but being a randomized 
trial, it was considered that there would be no bias.  
For operations performed as day-cases, admission to hospital post operatively for 
a wound problem was regarded as prolongation of hospital stay, as was delayed 
discharge of in-patients due to wound problems. 
For the other ASEPSIS criteria of additional treatment (antibiotics, drainage of pus, 
wound debridement), isolation of bacteria and prolongation of hospital stay, scores 
identical to the original ASEPSIS were awarded. Therefore, scores of 10, 5, and 10 
were awarded for antibiotics, drainage of pus and wound debridement respectively. 
Isolation of bacteria scored 10, and prolongation of stay scored 5. As in the original 
ASEPSIS, the 4 wound parameters were scored on each day of assessment, while 
the other criteria were scored once during the period of observation.  
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The ASEPSIS generates a daily wound parameter score, which is a sum of all 
scores awarded for the presence of the wound features on each day of 
assessment. In this trial, the maximum possible daily wound parameter score was 
18 and so maximum possible wound parameter score for the 5 days of assessment 
was 90. Where a patient had no wound problems, a score of 0 was awarded. 
Although the original ASEPSIS method did not utilize a daily score, it was decided 
that calculating a daily wound score would permit a detailed examination of the 
data, identifying the time points at which wound complications were most likely to 
occur, and the relative prevalence of each of the 4 wound parameters at each time 
point.  
A total ASEPSIS score was calculated by summing daily wound scores for all 5 
assessment days, together with any score for the other ASEPSIS criteria. In this 
trial, the maximum possible total score was 130. This could only have been 
achieved where a patient had maximum daily wound score on every day of 
assessment, and also received antibiotics postoperatively, underwent incision and 
drainage of a wound abscess, followed by wound debridement under general 
anaesthesia, and whose wound culture was positive for bacteria, and who was 
admitted to hospital with wound problems. The total score categorizes wound 
outcomes into satisfactory healing (score of 0-10), disturbed healing (11-20), minor 
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wound infection (21-30), moderate wound infection (31-40), and major wound 
infection (>40). 
A formal postoperative wound assessment was performed on day 14 by a blinded 
investigator. At this assessment, diaries were collected, and information on 
General Practitioner (GP) attendance for wound – related problems and 
requirement of antibiotic for perceived wound infection, was recorded. Information 
on GP attendance was obtained from patients, and no independent confirmation 
was obtained from GPs. As the post operative assessment took place after only 2 
weeks, recall was not a problem, and all patients were able to recall attendance at 
GP surgery, as well as which (if any) medications they received. 
Microbiological swab assessment where indicated, was left to the discretion of the 
GP or attending physician, in patients presenting with wound problems. Unblinding 
of patient and investigator took place at the end of the postoperative assessment, 
when the re-sealed randomization envelope was re-opened. 
Outcome measures 
Primary: 
 The incidence of wound complications, determined by an adapted version of the 
ASEPSIS wound scoring system. 
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Secondary: 
 Visit to the GP for a wound related problem, as well as the requirement of 
antibiotics in the postoperative period for a perceived wound infection. 
Tertiary: 
 The factors / variables associated with a an increased likelihood of wound 
complications, as determined by univariate and multivariable analyses  
Statistical analysis 
Data analysis was performed on an intention-to-treat basis, using SPSS for 
Windows version 12 (SPSS Inc., Chicago IL) and GLIM4 statistical packages. 
Inter-group analysis was performed using Mann Whitney test for continuous data 
and Chi square test for categorical data. Two-sided significance level was set at 
p<0.050. Statistical advice was provided by Dr Alan Rigby of the Academic 
Cardiology department, University of Hull.  
The primary outcome measure was a composite assessment, measured by 
calculating the daily wound parameter scores, and then generating the total 
ASEPSIS score by summing all the daily scores as well as the scores for additional 
treatment, isolation of bacteria and prolongation of hospital stay. The scores for 
each group were compared by parametric tests. As recommended in literature 
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(Perneger 1998) no adjustments were made in the p-values for multiple 
comparisons, but unadjusted p-values are reported. 
The relationship between the primary outcome measure and the explanatory 
variables was assessed by logistic regression from which odds ratios (ORs) and 
95% confidence intervals (CIs) were estimated. The OR is an approximation to the 
relative risk (Morris and Gardner 1988, Rigby 1999). Model building was based on 
backwards elimination (p for entry=0.05; p for removal=0.1), as this is preferable to 
forward selection (Sauerbrei 1999). Models were validated using re-sampling 
based on 10-fold cross-validation (Brieman and Spector 1992). The data was 
divided into 10 subsets of approximately equal size while maintaining the 
frequency of the primary outcome measure within each of the subsets. For each 
subset, a statistical model was generated using backwards elimination leaving out 
one subset at a time. Thus, for model 1 subset 1 was left out basing the analysis 
on the other 9 subsets and so on (Sauerbrei 1999). The frequency of the significant 
variables was tabulated for each of the 10 models. A final multivariable model was 
generated based on variables appearing in most subsets.  
Ethics 
Prior to the commencement of this trial, ethical approval was sought and obtained 
from the Hull and East Riding Local Research Ethics Committee. Ethical approval 
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was granted on 23rd September 2002 (ref LREC/08/02/135). The trial registry was 
available at www.controlled-trials.com (ISRCTN number 12467340). 
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4. RESULTS 
4.1. Study 1: An analysis of the suitability for endovenous ablation 
in patients with lower limb varicose veins 
Over the 12 month study period, 482 patients were added to the day case waiting 
list for varicose vein surgery. 328 (68%) were women, and 154 (32%) men; median 
age was 44 (IQR 36 – 56) years.  
339 patients (70%) were listed for primary unilateral SFJ ligation, GSV strip and 
stab avulsions, and so formed the cohort from which patients were selected. The 
remaining 30% of patients on the list (n = 143) were excluded for not meeting the 
primary inclusion criterion. These patients were listed as follows (figure 1.1) 
Short saphenous varicose vein surgery - 6% (n = 29) 
Redo surgery - 9% (n = 43) 
Bilateral varicose vein surgery - 15% (n = 71) 
150 of the 339 patients listed for primary unilateral SFJ ligation, GSV strip and stab 
avulsions, were invited for duplex scanning, and 112 (75%) attended. 
According to the set suitability criteria, 63 patients (56%) were found suitable for 
endovenous therapy, while 49 patients (44%) were found unsuitable as follows: 
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19 patients had an incompetent proximal thigh branch in addition to an 
incompetent GSV 
10 patients had a GSV diameter of <5mm at the knee 
6 patients wanted general anaesthesia 
1 patient preferred open surgery 
1 patient had no demonstrable SFJ incompetence or GSV reflux on duplex scan 
12 patients were unsuitable for a combination of reasons, mainly a small 
perigenicular GSV and incompetent thigh tributary (figure 1.2). 
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Figure 1.1 Flow chart of study 1. IQR interquartile range; HTSA high tie, strip and 
avulsions; SSV small saphenous vein; DUS duplex ultrasound scan. Figures are 
numbers of invited patients; figures in parenthesis are percentages of the group of 
patients in that arm.
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39%
20%
12%
2%
2%
25%
Incompetent thigh branch (19) Small perigenicular GSV (10)
Wanted GA (6) Wanted surgery (1)
No SFJ/GSV reflux (1) Combination of reasons (12)
Figure 1.2 Reasons for unsuitability for EVLA. GA general anaesthetic; SFJ 
sapheno femoral junction; GSV great saphenous vein . Figures in legend are the 
actual number of patients in each category. Total number of unsuitable patients is 
49     
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4.2 Study 2: An analysis of the feasibility and acceptability of 
EVLA and ambulatory phlebectomy in patients with lower limb 
varicose veins 
The study population comprised 67 patients, 31 men and 36 women; median age 
49 (IQR 35 – 58) years. CEAP class was C2 = 45, C4 = 24, C5 = 1. 70 unilateral 
EVLA procedures were carried out in these patients (3 patients with bilateral 
varicose veins underwent staged procedures).  
Assessments and follow up 
Patient follow up was 100% at 1 week (n = 70 limbs) and 97% at 6 weeks (n = 68 
limbs); 1 patient was lost to follow up, while 1 patient missed appointment but 
turned up for the 12 week visit. 70% (n = 49 limbs) had been seen at 12 weeks 
follow up, when results were analysed. 
Outcomes 
Pain scores (figure 2.1) 
Median pain score on day 1 was 1.6 (IQR 0.3 – 4.8); on day 4 was 0.3 (IQR 0 – 
1.4) and on day 7 was 0.2 (IQR 0 – 1.1). 
Occlusion rates (figure 2.2) 
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GSV occlusions rate was 98.6% (69 of 70 limbs) at 1 week, and 95.9% (47 of 49 
limbs) at 12 weeks. SFJ occlusion was seen in 97.1% (n = 68 of 70) of limbs at 1 
week and 95.9% (n = 47 of 49) of limbs. 
Subsequent treatment  
Three limbs (4.4%) in three patients required injection sclerotherapy after 6 weeks, 
for residual varicosities. All 3 patients had thread veins. 1 patient (1.4%) underwent 
re-do phlebectomy for residual varicosities. 
Patient satisfaction (figure 2.3) 
Median patient satisfaction with cosmetic appearance was 9.6 (IQR 9.2 – 10) and 
for overall satisfaction with treatment was 9.8 (IQR 9.5 – 10). 
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Figure 2.1 Median pain scores, post EVLTAP. Pain assessed by visual analogue 
scale from 0 (no pain) to 10 (maximum pain). 
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Figure 2.2 Occlusion rates post EVLTAP. GSV Great saphenous vein; SFJ 
sapheno femoral junction. Percentages are proportions of limbs assessed at both 
time points: 70 limbs at 1 week and 49 limbs at 3 months 
  
111 
 
  
Figure 2.3 Patient satisfaction post EVLTAP. Satisfaction was assessed by a visual 
analogue scale from 0 (completely dissatisfied) to 10 (completely satisfied) 
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4.3. Study 3: A non randomised controlled trial of endovenous 
and surgical treatment of patients with varicose veins 
Patients  
Surgery Group: 62 patients were recruited; 19 men and 43 women, median age 49 
years (IQR 35 – 61). 
EVLA Group: 70 consenting suitable patients (33 men, 37 women), median age 49 
years (IQR 35 – 58) were recruited into the EVLA arm. 
Assessments and Follow up  
At 1, 6 and 12 weeks was 100%, 85% and 47% following surgery, and 100%, 77% 
and 70%, following EVLT. 
Outcomes 
All procedures in the surgery group were successfully carried out as day cases, 
except for 5 patients who were admitted overnight (2 for social reasons and 3 for 
post op pain requiring parenteral analgesia).  
All procedures in the EVLA group were performed successfully as day cases under 
local anaesthetic with no admissions.  
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There were no major complications such as skin burns, DVT, arteriovenous fistula, 
major vascular and nerve injuries, or severe wound infection in either group.  
Occlusion rates 
 EVLA group: At 1 & 12 weeks SFJ occlusion rates on duplex ultrasound were 97 & 
96 % respectively. GSV occlusion rates at the same time points were 99% & 96%. 
Surgery group: All patients had successful stripping of the GSV. Duplex scans 
were not routinely performed following surgery. 
Baseline parameters (Table 3.1): The groups were well matched for age, gender 
and SF-36 domains except PF, BP and VT, where the surgery group had 
significantly lower baseline scores. The surgery group also had higher baseline 
AVVQ and VCSS scores.  
SF-36 results 
Surgery group (Table 3.2): At 1 week, there was a statistically significant 
deterioration in the SF-36 domains of PF, RP, BP and SF. Over the total study 
period, all domain scores equalled or surpassed baseline scores with statistically 
significant improvement in the PF, RP, BP, VT, SF and MH domains. 
EVLA group (Table 3.3): There was no significant deterioration seen in any domain 
at 1 week. Over the total study period, all domain scores equalled or surpassed 
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baseline scores with statistically significant improvement in the PF, RP, BP, GH, 
VT and SF domains. 
Intergroup comparison (Figures 3.1 – 3.4): At 1 week scores in the PF, RP, BP and 
SF domains were significantly worse in the surgery group. At 6 weeks scores in the 
PF and RP domains remained significantly worse in the surgery group, however at 
12 weeks, there were no differences in any of the SF36 domains between groups. 
AVVQ results  
Surgery group (Table 3.2): At 1 week there was a significant deterioration in AVVQ. 
Over the total study period, a significant improvement in AVVQ score was 
observed, falling to a median value of 4.4 at 12 weeks representing a 74% 
improvement from baseline.  
EVLA group (Table 3.3): At 1 week there was a significant deterioration in AVVQ. 
Over the total study period, a significant improvement in AVVQ score was 
observed, falling to a median value of 0.6 at 12 weeks representing a 95% 
improvement from baseline.   
Intergroup analysis (Figure 3.5): At 1 week there was no significant difference in 
AVVQ scores between the two groups. At 6 and 12 weeks the EVLT group 
demonstrated significantly better AVVQ scores than the surgery group. 
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VCSS results  
Scores were assessed in both groups at baseline and at 12 weeks.  
Surgery group (Table 3.2): Significant improvement was observed with VCSS 
scores falling from 6 (4 – 8) at baseline, to 0 (0 – 1) at 12 weeks. 
EVLA group (Table 3.3): Significant improvement was observed with VCSS scores 
falling from 4 (3 – 5) at baseline, to 0 (0 – 1) at 12 weeks. 
Intergroup analysis (Figure 3.6): Demonstrated no difference in scores between 
groups at 12 weeks.  
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Parameter Surgery EVLA P value 
Age  49 (35,61)  49 (35,48) .671 
Sex M = 19 
F = 43 
M =33 
F = 37 
.083 
Physical Function (PF) 80 (55,91) 90 (80,100) .003 
Role Physical (RP) 75 (50,100) 100 (25,100) .630 
Bodily Pain (BP) 52 (51,74) 74 (51,84) .009 
General Health (GH) 77 (70,87)  82 (62,92) .142 
Vitality (VT) 60 (40,80) 73 (60,80) .009 
Social Function (SF) 88 (62,100) 100 (75,100) .057 
Emotional Role (RE) 100 (66,100) 100 (100,100) .486 
Mental Health (MH) 84 (67,92) 88 (76,92) .239 
AVVQ 16.6 (12.6,20.6) 11.1 (8.9,17.4) .001 
VCSS 6 (4,8) 4 (3,5) .000 
Table 3.1 Baseline Parameters. Values are Median (IQR). AVVQ-Aberdeen 
Varicose Vein Questionnaire; VCSS-Venous Clinical Severity Score 
 
Measure 
 
Pre Op 1 week P* 
value 
(Pre op 
to 
1 week) 
6 weeks 12 weeks P** value 
(Across 
all 
time 
points) 
AVVQ 
16.6 
(12.6-
20.6) 
22  
(18.1-
26.7) 
.001 13.2 (7.9-
17.7) 
4.4 (1.8-
9.9) 
.000 
VCSS 6 (4-8)    0 (0-1) .000 
PF 80 (55-91) 40 (18-
75) 
.000 85 (60-
95) 
95 (87-
100) 
.000 
RP 75 (50-
100) 
0 (0-25) .000 100 (0-
100) 
100 (100-
100) 
.000 
BP 52 (51-74) 41 (31-
62) 
.000 74 (62-
100) 
74 (52-
100) 
.000 
GH 77 (70-87) 80 (66-
87) 
.483 82 (67-
93) 
82 (64-
91) 
.132 
VT 60 (40-80) 55 (38-
70) 
.069 65 (50-
80) 
70 55-85) .000 
SF 88 (62-
100) 
63 (37-
75) 
.000 100 (68-
100) 
100 (87-
100) 
.000 
RE 100 (66-
100) 
100 (66-
100) 
.551 100 (66-
100) 
100 (100-
100) 
.869 
MH 84 (67-92) 84 (68-
92) 
.873 88 (72-
92) 
88 (80-
100) 
.001 
 
Table 3.2 Quality of Life outcomes following surgery. Values are Median (IQR).  
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Measure 
 
Pre Op 1 week P* 
value 
(Pre op 
to 
1 week) 
6 weeks 12 weeks 
 
 
P** value 
(Across 
all 
time 
points) 
AVVQ 
11.1 
(8.9-
17.4) 
15.7 
(12.6-
22.3) 
.000 4.7 (2.2-
6.7) 
0.6 (0-
4.4) 
.000 
VCSS 4 (3-5)    0 (0-1) .000 
PF 90 (80-
100) 
90 (90-
100) 
.070 100 (90-
100) 
100 (86-
100) 
.001 
RP 100 (25-
100) 
75 (0-100) .037 100 (75-
100) 
100 (81-
100) 
.000 
BP 74 (51-
84) 
72 (42-84) .106 84 (73-
100) 
92 (72-
100) 
.000 
GH 82 (62-
92) 
82 (72-92) .227 86 (74-
97) 
82 (73-
97) 
.007 
VT 73 (60-
80) 
70 (55-80) .370 75 (60-
90) 
75 (60-
85) 
.001 
SF 100 (75-
100) 
88 (75-
100) 
.033 100 (75-
100) 
100 (75-
100) 
.008 
RE 100 
(100-
100) 
100 (100-
100) 
.439 100 (100-
100) 
100 (100-
100) 
.039 
MH 88 (76-
92) 
88 (76-92) .996 88 (80-
92) 
90 (70-
96) 
.167 
 
Table 3.3 Quality of Life outcomes following EVLA. Values are Median (IQR) 
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p< 0.01 p< 0.01 p< 0.01 p=0.236
 
 
Figure 3.1 Intergroup comparison of Physical Function (PF) domain of the  
SF 36. Box represents IQR; line within box represents median value; whiskers 
represent maximum and minimum values. No outliers present within data set 
  
120 
 
pre week 1 week 6 week 12
Time Points
0
20
40
60
80
100
R
o
le
 P
h
y
s
ic
a
l
 
Surgery
EVLT
p< 0.01 p< 0.01 p< 0.01 p=0.993
 
Figure 3.2 Intergroup comparison of Physical Role (RP) domain of the SF 36. 
Box represents IQR; line within box represents median value; whiskers 
represent maximum and minimum values. No outliers present within data set 
 
  
121 
 
pre week 1 week 6 week 12
Time Points
0
20
40
60
80
100
B
o
d
il
y
 P
a
in
 
Surgery
EVLT
p< 0.01 p< 0.01 p=0.302 p=0.808
 
 
Figure 3.3 Intergroup comparison of Bodily Pain (BP) domain of the SF 36. Box 
represents IQR; line within box represents median value; whiskers represent 
maximum and minimum values. No outliers present within data set 
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Surgery
EVLT
p< 0.01 p< 0.01 p= 0.154 p= 0.267
 
Figure 3.4 Intergroup comparison of Social Functioning (SF) domain of the  
SF 36. Box represents IQR; line within box represents median value; whiskers 
represent maximum and minimum values. No outliers present within data set 
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Figure 3.5 Intergroup comparisons of the Aberdeen Varicose Vein 
Questionnaire (AVVQ) scores. * indicates statistically significant difference 
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Figure 3.6 Venous Clinical Severity Scores (VCSS) in both groups at baseline, 
and 12 weeks post treatment. Median scores decreased to 0 in both groups, at 
12 weeks post treatment. 
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4.4. Study 4: A randomised controlled trial of prophylactic 
antibiotics in patients undergoing surgical treatment of 
varicose veins 
It was estimated that recruitment would be completed in about 24 months, but it 
took 31 months to complete recruitment. In this period, 456 patients were 
approached to enter the trial. 454 patients agreed to participate, while 2 patients 
declined. 11 other patients were excluded based on the preset exclusion 
criteria. A total of 443 patients were therefore randomized. All the randomized 
patients received their allocated treatment.  
All treated patients whose data were incomplete (failed to attend follow up clinic 
and/or return wound diary, or missing diaries) were excluded from the final 
analysis. 212 and 214 patients were analysed in the treatment and control 
groups respectively. The overall attrition rate was about 4%. The consort 
diagram (figure 4.1), shows the flow of patients in the study. The groups were 
well balanced, as shown in table 4.1. 
ASEPSIS Scores 
Total ASEPSIS Score 
Not surprisingly, varicose vein surgery being clean surgery, the majority of 
patients in both groups (80.6% treatment group; 67.3% control group) had total 
ASEPSIS score of ≤10 (indicating satisfactory healing; table 2). Overall 
however, significantly higher total ASEPSIS scores were recorded in the control 
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group, with median (inter-quartile range) score of 6 (0 – 15), versus 3 (0 – 9) in 
the treatment group; p = 0.013 (figure 4.2). 21 patients (9.9%) in the treatment 
group and 39 (18.2%) in the control group had total ASEPSIS score ≥ 21, which 
by ASEPSIS criteria, defines wound infection.  
ASEPSIS Component Scores 
The data was broken down into the various components of the ASEPSIS as 
described in the methods. The various component scores are as follows: 
Additional Treatment 
The requirement for antibiotics post operatively is reported below in section 4.3.  
Two patients (0.9%) in the control group were admitted with groin wound 
abscess, and both underwent incision and drainage. No patient in the treatment 
group was admitted, and none required incision and drainage. No patient in 
either group required debridement of a severe wound infection. 
Serous Discharge 
The experience of serous discharge from the groin wounds was analysed on 
each day of assessment (3, 5, 7, 9 and 10). The greatest numbers of patients 
experiencing serous discharge occurred on day 3 in both groups (7.5% in the 
treatment group, and 9.3% in control group; p = 0.51). There was no difference 
in this outcome, between groups at anytime of observation. 
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Wound Erythema 
This was again assessed on days 3, 5, 7, 9 and 10. The experience of wound 
erythema was similar in both groups, except on day 7, when significantly more 
patients in the control group reported wound erythema. As with serous 
discharge, the greatest number of patients reported erythema on day 3. 
Purulent Discharge 
Purulent discharge from wounds was proportionately more common in the 
control group at each time point, reaching statistical significance on days 3 
(8.9%, vs. 3.8% p = 0.032), 5 (11.2% vs. 3.8%, p = 0.004), and 7 (12.1% vs. 
2.8%, p = 0.001) in the control and treatment groups respectively. In all, 43 
(20.1%) in the control group and 22 (10.4%) patients in the treatment group 
discharged purulent exudates on at least one day during the period of 
observation. This difference was significant (p = 0.005). 
Separation of Wound Edges 
There were proportionately more patients in the control group reporting 
separation of wound edges in the control group, on each day of assessment. 
The difference however, did not reach statistical significance at any time point.  
Isolation of Bacteria 
As stated in the methods section, the decision to swab wounds was left to the 
discretion of the GPs or attending practitioner in patients presenting with wound 
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problems in the post operative period. Overall, four wounds were swabbed for 
microbiological cultures in the treatment group, of which 1 (25%) was positive 
(Staphylococcus epidermidis). In the control group, 5 of 10 cultures (50%) grew 
Staphylococcus aureus. 
Prolongation of Stay 
There was no delayed discharge from hospital as a result of wound issues in 
either group. As stated earlier, 2 patients (0.9%) were admitted post operatively 
for incision and drainage of groin wound abscess.  
The results of the daily ASEPSIS wound component assessment are 
summarised in table 4.3, while the proportion of patients with daily total wound 
scores >10 is summarised in table 4.4; these show that daily scores were 
significantly higher (indicating worse wound outcome) in the control group, as 
compared with the treatment group. 
Day 14 Assessment 
There were no significant wound differences between the groups as assessed 
by a blinded observer using ASEPSIS criteria on day 14 (table 4.5).  
General Practitioner (GP) Attendance 
Thirty-four patients (16%) in the treatment group reported visiting their GP post 
operatively for problems in their groin wounds, compared with 52 patients 
(24.3%) in the control group. Thus patients receiving prophylactic antibiotic, 
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were significantly less likely to visit their GP (OR 0.595; 95% CI 0.369 – 0.961; 
p = 0.034).  
GP Prescription of Antibiotics 
Treatment group patients were less likely to receive antibiotics in the 
postoperative period for a perceived wound infection: 10 patients (4.7%) versus 
29 patients (13.5%) (OR 0.316; 95% CI 0.152 – 0.657; p = 0.002).  
Logistic Regression Analyses 
Univariate Analysis 
The results of the univariate analysis are shown in table 4.6. Univariate analysis 
showed that receiving antibiotics was associated with the odds of a good 
outcome, defined as satisfactory healing (a total ASEPSIS score of ≤ 10). 
Increasing BMI was associated with a poorer outcome as was redo surgery. A 
CEAP score ≥ 4 was not significantly associated with the odds of having a poor 
outcome, though these patients in general had higher ASEPSIS score. There 
was no significant relationship between wound outcome and age.  In 
combination, five variables (receiving antibiotics, BMI, smoking, redo surgery 
and gender) appeared in 10 models. Receiving antibiotics and BMI appeared in 
all 10, current smoking (indicative of a poor outcome) appeared in 7; redo 
surgery in 3, while gender appeared in 1. Several models appeared more than 
once. 
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Multivariable Analysis 
The multivariable model consisted of three variables only: randomization to 
antibiotics (OR=2.2, 95% CI=1.3-3.6, p=0.003), BMI (OR=0.92, 95% CI=0.87-
0.97, p=0.005) and current smoking (OR=0.5, 95% CI=0.3-0.9, p=0.03) which 
were adjusted for each other.  These variables were selected as the most 
frequently occurring from the 10-fold cross-validation exercise.  
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Figure 4.1 CONSORT diagram. Flow chart of participants through trial
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 Treatment Group Control Group 
Number of patients 
 
212 214 
 
Female 143 128 
Median Age (IQR) 46 (37 – 54) 49 (37 – 59) 
Bilateral Surgery 65 (130 limbs) 60 (120 limbs) 
Redo Surgery 28 27 
Median BMI (IQR) 27 (24 – 30) 27 (24 – 29) 
Current Smoking 60 41 
CEAP       C1 - - 
C2 150 162 
C3 2 1 
C4 57 47 
C5 3 1 
C6 - 1 
Unclassified   - 2 
 
Table 4.1 Baseline demographic data; IQR: interquartile range; BMI: body mass 
index; CEAP: clinical-aetiologic-anatomic-pathophysiologic (C1-telangiectasia, 
C2-varicose veins, C3-oedema, C4-skin changes, C5-healed ulcers, C6-active 
ulcers); current smoking was arbitrarily defined as smoking of at least 5 
cigarettes daily for a minimum of 3 months, at the time of treatment. 
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ASEPSIS Score 
Treatment group 
n (%) 
Control group 
n (%) 
0 – 10 171 (80.7) 144 (67.3) 
11 – 20 20 (9.4) 31 (14.5) 
21 – 30 10 (4.7) 17 (7.9) 
31 – 40 5 (2.4) 6 (2.8) 
> 41 6 (2.8) 16 (7.5) 
 
Table 4.2: Stratified total ASEPSIS score; Chi-square for trend (1 df = 4.35), 
p=0.037 
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Figure 4.2: Total ASEPSIS score; bar within box represents median score; box 
represents interquartile range (IQR); whiskers represent 1.5 x IQR; circles 
represent outliers <3 x IQR, and stars represent extreme outliers >3 x IQR. The 
median (IQR) was 3 (0-9) and 6 (0-15) in the treatment and control groups 
respectively; p=0.013. Analysis done using Mann Whitney test.  
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Feature and 
Day of assessment 
Groin wounds affected n (%) P value 
Treatment group Control group 
Erythema    
3 73 (34.4) 85 (39.7) 0.27 
5 55 (25.9) 70 (32.7) 0.13 
7 34 (16.0) 50 (23.4) 0.045 
9 29 (13.7) 39 (18.2) 0.28 
10 22 (10.4) 34 (15.9) 0.09 
Serous discharge    
3 16 (7.5) 20 (9.3) 0.51 
5 9 (4.2) 12 (5.6) 0.52 
7 8 (3.8) 4 (1.9) 0.23 
9 6 (2.8) 5 (1.9) 0.74 
10 4 (1.9) 3 (1.4) 0.68 
Wound separation    
3 9 (4.2) 12 (5.6) 0.52 
5 12 (5.7) 17 (7.9) 0.35 
7 11 (5.2) 21 (9.8) 0.07 
9 14 (6.6) 18 (8.4) 0.48 
10 11 (5.2) 18 (8.4) 0.19 
Purulent discharge    
3 8 (3.8) 19 (8.9) 0.032 
5 8 (3.8) 24 (11.2) 0.004 
7 6 (2.8) 26 (12.1) 0.001 
9 8 (3.8) 15 (7.0) 0.14 
10 5 (2.4) 9 (4.2) 0.29 
Table 4.3 Wound characteristics: Erythema, serous discharge, purulent 
discharge and wound separation 
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Day of 
assessment 
ASEPSIS Wound Score > 10 
% of patients (range of all observed 
scores) 
P 
value* 
Treatment group Control group 
Day 3 2.4 (0 – 15) 2.3 (0 – 18) 0.043 
Day 5 2.4 (0 – 15) 5.6 (0 – 18) 0.032 
Day 7 2.8 (0 – 18) 5.6 (0 – 15) 0.003 
Day 9 2.8 (0 – 15) 5.1 (0 – 15) 0.33 
Day 10 1.4 (0 – 15) 3.3 (0 – 15) 0.10 
 
Table 4.4 Proportion of patients with daily total wound scores >10. Range of all 
observed scores in each group on the day, shown in parenthesis; *p value 
based on all daily scores; Mann Whitney test 
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 Treatment group 
n (%) 
Control group 
n (%) 
*p value 
Erythema 4 (1.9) 10 (4.6) 0.107 
Serous exudates 3 (1.4) 4 (1.9) 0.713 
Purulent exudates 1 (0.5) 1 (0.5) 0.997 
Separation 5 (2.4) 13 (6.1) 0.057 
 
Table 4.5 Day 14 wound assessment. *Mann Whitney test  
 
 
 
 
 
 
 
  
138 
 
Variable 
 
Outcome (n) Odds ratio  
(95% CI) 
P value 
poor good 
Age*   0.99 (0.98-1.01) 0.55 
BMI*    0.94 (0.89-0.99) 0.009 
Gender     
Female 63 208 1.0 
0.08 
Male 48 107 0.7 (0.4-1.1) 
Redo Surgery     
No 86 261 1.0 
0.16 Yes 20 35 0.6 (0.3-1.1) 
Unknown  5 19 1.3 (0.5-3.6) 
Smoking     
Never 41 139 1.0 
0.08 
Current 65 36 0.5 (0.6-0.9) 
Ex 20 72 1.1 (0.6-2.0) 
Unknown  14 39 0.8 (0.4-1.6) 
CEAP class     
C2-3 76 239 1.0 
0.16 C4-6 35 74 0.7 (0.1-1.1) 
Unknown  0 2 X 
Randomisation to antibiotics     
No 70 144 1.0 
0.002 
Yes 41 171 2.0 (1.3-3.1) 
Table 4.6 Univariate analyses. * analysed as continuous variables; X not 
possible to estimate odds ratio due to cell zero
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DISCUSSION 
Varicose veins are common, and in the United Kingdom, they constitute a huge 
burden to the National Health Service, in terms of the surgical workload, 
outpatient attendances at primary and secondary health, as well as cost of 
management of complications (Michaels, Campbell et al. 2006). Besides the 
burden on healthcare resources, varicose veins also cause problems including 
Quality of Life limitations for sufferers, with implications for their physical, mental 
and economic health. The appropriate and optimal management of varicose 
veins is therefore both desirable and necessary, especially in the current 
economic climate.  
This current work focused on optimizing varicose vein management. The 
treatment of varicose veins is evolving, with minimally invasive techniques 
emerging in the last few years as alternatives to conventional surgery. These 
are aimed at reducing surgical morbidity, shortening recovery period and 
providing comparable results (Beale, Mavor et al. 2004). In addition, minimally 
invasive techniques may offer acceptable options to the millions who have 
varicose veins but are unwilling or unable to undergo surgery (Min, Khilnani et 
al. 2003). When endovenous laser therapy (EVLT) was first introduced, it was 
principally a technique for treating GSV truncal varicosity. The case reports and 
series at that time indicated (quite correctly), that the new minimally invasive 
technique was likely to be safe and effective. It was therefore a technique we 
were quite eager to introduce in the management of our patients. 
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In designing our initial study, we aimed to limit technical failures during the early 
stages of rendering an EVLA service for varicose veins. The eligibility criteria 
were deliberately kept rigid and narrow. There were 339 patients listed for 
primary GSV surgery, making up 70% of the varicose vein surgery waiting list. 
This proportion, as well as the distribution of primary and secondary 
procedures, and the different rates of junctional incompetence, is in keeping 
with the general findings of patterns of lower limb varicosities in other studies 
(Goren and Yellin 1990, Beale and Gough 2005, Cheatle 2005). 
Patients listed for re-do surgery were excluded. This group accounted for 9% of 
patients on the list. Although the rates of recurrent varicose veins vary widely, at 
least 20% of varicose vein operations are performed for recurrent disease (van 
Rij, Jones et al. 2004). The exact reason for a low re-do surgery list among our 
cohorts is unknown. Possible explanations would include: the fact that only the 
day-case list was screened, leaving out those listed for in-patient treatment; it 
may also be an indication of low prevalence of recurrent disease in our 
catchments area; or that our patients were not particularly bothered by recurrent 
varices, if they were not causing significant health – related problems. Because 
stripping of the GSV has been performed fairly routinely as a primary 
procedure, it was our view that there will be a relatively low number of patients 
with recurrent varicose veins who had an anatomically intact, albeit incompetent 
GSV; therefore, we excluded these patients, because the majority of them were 
thought unlikely to be suitable for EVLA. In retrospect, judging from today’s 
practice, several of these patients with recurrent disease would have been 
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suitable for EVLA. Laser ablation is now routinely performed for recurrent 
varicose veins. There are however necessary criteria for suitability. 
Theivacumar and Gough recently published on EVLA for recurrent varicose 
veins (Theivacumar and Gough 2011). They only included patients who had at 
least 10cm of truncal refluxing vein, with a diameter of >3mm proximal to the 
varicosities. Although this was a local guideline, it was necessary to have a 
sufficient length of vein that could be ablated in order to abolish reflux. The 
presence of neovascularisation was not an exclusion criterion, but such patients 
did not have ablation up to the major junction (SFJ or SPJ), but about half of 
this cohort of patients had foam injection via the laser catheter beyond the point 
of EVLA. By their selection criteria, 95 of 127 (75%) patients with recurrent 
varicose veins were suitable for EVLA. van Groenendael and colleagues 
performed a retrospective analysis of patients with recurrent varicose veins of 
the GSV system, treated by surgery or EVLA (van Groenendael, van der Vliet et 
al. 2009). They excluded patients who had no identifiable connection between 
the superficial varicosities and the SFJ, as well as patients with a GSV <4mm. 
By their criteria, suitability for EVLA was only 31% of patients. Most of their 
anatomical unsuitability was as a result of excessive tortuosity.   
In our suitability study, we also excluded 71 patients (15%) listed for bilateral 
surgery. Campbell and colleagues, in investigating patient preference for 
treatment of their varicose veins, showed that patients preferred having a single 
bilateral operation even if it involved in – patient treatment, to having two 
unilateral day case procedures (Campbell, Dimson et al. 1998). The concern at 
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the time, of exceeding a safe dose of local anaesthetic medication if bilateral 
procedures were performed at a single sitting meant exclusion of these patients. 
It was felt likely however, that a similar percentage of these patients will be 
suitable for EVLT. As technical skills have improved, the total dose of local 
anaesthetic use has also decreased. It is now fairly routine to perform bilateral 
EVLA or EVLA of the SSV and GSV at a single sitting.   
29 (6%) patients with SPJ incompetence / SSV reflux were also excluded. 
EVLA for SSV varicosities was considered technically more difficult, with greater 
potential for causing harm, and its efficacy and safety had not yet been clearly 
demonstrated when this study was commenced. The initial reluctance by 
various EVLA practitioners to perform ablations of the short saphenous vein 
may have been related to the concerns about proximity of the sural nerve to the 
small saphenous vein, as well as thrombus extension into the popliteal vein 
(Gibson, Ferris et al. 2007). At this present time, laser ablation for small 
saphenous varicosity has become common place, and is in fact the preferred 
treatment over standard surgery, with reported better efficacy and less 
complications (Tellings, Ceulen et al. 2011). In comparison to laser ablation of 
the great saphenous vein however, treatment of the SSV is associated with 
more morbidity. This was recently demonstrated in our unit, in a study carried 
out by Carradice and colleagues, who performed a retrospective cohort analysis 
comparing response following treatment (both standard surgery and 
endovenous laser ablation) of great and small saphenous vein incompetence. 
They found a significantly worse deterioration in Aberdeen Varicose Vein 
  
143 
 
Questionnaire (AVVQ) Scores in the early post intervention period, with 
treatment of small saphenous than was observed after similar treatment of the 
great saphenous vein (Carradice, Samuel et al. 2011).  
Theivacumar and colleagues reported in 2007, their initial experiences with 
EVLA of short saphenous vein varicosities (Theivacumar, Beale et al. 2007). 
They had good initial and 3 months technical success rates, with improved 
AVVQ scores at 3 months and, and minimal complication rates. They did not 
specify their suitability criteria, but they found 72% of patients with primary SSV 
varicosity, and 69% of patients with recurrent disease, suitable for EVLA. The 
high rate of EVLA suitability in recurrent SSV varicose veins as compared with 
recurrent GSV varices is presumably due to the fact that the short saphenous 
vein is not routinely stripped at open surgery, and therefore there is often an 
intact SSV which is amenable to laser ablation. Towards the end of our study, 
we began performing a randomised controlled trial of surgery versus EVLA for 
SSV incompetence, and the majority of patients were suitable for laser ablation 
and therefore eligible for the trial. However, at the time of initiation of the laser 
suitability study, it was decided to exclude patients with SSV varicosities, as 
EVLT at that time, was largely a procedure for the treatment of primary GSV 
incompetence. 
While it would have been desirable to scan all eligible patients on the list, invited 
patients were limited to 150 as a consequence of costs. This sample size of 
randomly selected patients would have been a fair representation of the 339 
patients on the waiting list for GSV surgery. The response rate (of invited 
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patients who attended for scanning) was 75%, which was an acceptable 
response rate. Based on our starting suitability criteria, 56% of patients (n = 63 
of 112) were found suitable for EVLT. This is a little less than we expected, and 
the 62% eligibility which was reported by Beale et al (Beale, Mavor et al. 2004), 
but this was no doubt due to the strict suitability criteria used.  
In exploring the causes of unsuitability, the major proportion of our patients 
(39%; n = 19/49) was unsuitable as a result of an incompetent major thigh 
tributary of the GSV. Almost all of these patients also had an associated 
incompetent GSV. These tributaries are often very tortuous and therefore 
difficult to canulate and pass a laser fibre through. In addition, with tributaries 
that drain into the GSV close to the SFJ, the risks of residual reflux are high, 
except they are also laser ablated. 
10 patients (20%) had a GSV with a diameter of less than 5 mm around the 
knee. Such small veins were associated with a high “failure to canulate” rate. As 
we aimed to keep this to a minimum and avoid stab – wound / cut – down vein 
canulation, we were of the opinion that this exclusion criterion was essential. 
There is a minimum vein size to allow for cannulation and catheter insertion for 
laser ablation. With better skills, as well as the development of micro puncture 
sets, it is now possible to cannulate even small diameter veins that were 
excluded in the early days of laser ablation. van Groenendael et al excluded 
patients whose GSV was less than 4mm (van Groenendael, van der Vliet et al. 
2009), while Theivacumar and Gough used a 3mm cut off (Theivacumar and 
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Gough 2011). In the on-going Comparison of Laser Ablation Sclerotherapy and 
Surgery (CLASS) multicentre trial, a minimum size of 3mm is set. 
A small number of patients will always prefer a general anaesthetic (Proebstle, 
Lehr et al. 2002), or not want to undergo a new procedure, preferring the “gold 
standard” or “old and trusted”. Whilst EVLA can be performed under general 
anaesthesia, this would seem to negate many of its benefits such as patient 
feed back during the procedure, short recovery time, and immediate patient 
ambulation (Min and Khilnani 2005). 
There are patients who may be unsuitable for more than one reason. In our 
cohort, 25% (n = 12) of patients were unsuitable for multiple reasons. Most 
common combination of reasons was a small perigenicular GSV and a refluxing 
antero-lateral thigh (anterior accessory GSV) branch. These patients were 
offered open surgery. In the present day practice of EVLA, these do not 
constitute non suitability for laser ablation. If an accessory anterior GSV is 
incompetent, it can be laser ablated so long as it is not too tortuous, and it is of 
adequate calibre (Theivacumar, Darwood et al. 2009, Chaar, Hirsch et al. 
2011). A more proximal point of cannulation can and has been used to 
overcome small peri-genicular GSV. 
The techniques, indications, and evidence for EVLA have evolved and 
advanced in the years since this study was performed. As has already been 
alluded to, many of the exclusion criteria set in this study are no longer 
considered as contraindications for EVLA. It is now routine for large thigh 
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tributaries / accessory saphenous veins (if not too tortuous), SSV, recurrent, 
and bilateral varicose veins to be treated by laser ablation (Gloviczki, Comerota 
et al. 2011). Several authors have reported successful ablation of the SSV, with 
excellent clinical outcomes and good safety profiles (Knipp, Blackburn et al. 
2008, Huisman, Bruins et al. 2009). Theivacumar and Gough  reported their 
experience with laser ablation of recurrent varicose veins of both the GSV and 
SSV, with similar technical and clinical success, as well as procedural 
complication rates as primary vein ablation (Theivacumar and Gough 2011). 
As already alluded to, there have been advances in the management of 
varicose veins, and the recent and on-going endovascular revolution has seen 
‘recent technologies’ quickly become ‘yesterday’s toy’. The main critique of the 
EVLA suitability study really lies with this issue of timeliness. The findings from 
the study have now become dated, and as already been alluded to, it would be 
erroneous to maintain that only about half of all varicose veins are suitable for 
EVLA. At the time of designing the study, endovenous laser ablation was in its 
infancy, and there were many who were sceptical as to the true value of this 
new technique. It was also, largely a procedure performed on GSV varicosities. 
It was therefore necessary to be perhaps over selective in the suitability criteria 
designed for the study. Also, because skills were only just being developed, 
technically “challenging” cases were deemed unsuitable. As skills have 
developed, these cases are now known to be suitable for EVLA.  
In the present day practice of endovenous laser ablation, the combination of 
increased experience and technical ability, the development of improved and 
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more user friendly ultrasound scanners and sonographic technology, as well as 
newer accessories and kits such as the micro puncture kits and hydrophilic 
wires and catheters, it is conceivable that a significant proportion of varicose 
veins can be treated either in whole, or at least partly by endovenous laser 
ablation. While no recent study has looked at proportion of varicose veins 
suitable for EVLA, anecdotal evidence from daily EVLA practice would suggest 
that the majority of varicose veins (certainly well above the 56% in our trial) 
would be suitable for laser ablation.  
When EVLT was introduced, the standard was to perform laser ablation of the 
truncal vein and leave treatment of branch / tributary varicosities for about 4 to 6 
weeks (Min, Zimmet et al. 2001, Navarro, Min et al. 2001). In many cases, this 
remains the standard practice for laser ablation (Khilnani, Grassi et al. 2010). 
While this makes the procedure shorter, there is the disadvantage of repeated 
visits for further treatment, which is estimated to be necessary in 30% – 99% of 
cases (Beale, Mavor et al. 2004). This may be unappealing to patients and may 
reduce cost effectiveness (Campbell, Dimson et al. 1998, Kluner, Fischer et al. 
2005). It was therefore appealing to explore the possibility of performing truncal 
vein ablation, along with phlebectomies of tributary varicosities as a combined 
procedure. Should this procedure be feasible, then it should not detract from the 
‘minimally invasive’ nature of EVLA, and be acceptable to patients, with good 
efficacy and safety profile. The EVLTAP procedure was developed to address 
these issues.  
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This study demonstrated that EVLTAP did not significantly increase patient 
discomfort or pain. Patients in this study reported minimal pain, comparable to 
that reported by practitioners of staged treatments. Unlike the experience of Min 
and Khilnani (Min and Khilnani 2005), our patients who underwent EVLTAP did 
not complain of delayed tightness post procedure. This may be because non 
steroidal anti inflammatory medications were routinely prescribed post 
procedure. The absence of this delayed tightness did not translate to treatment 
failure.  
In our experience, EVLTAP took a median time of 69 (IQR 60 – 80) minutes to 
perform, from vein cannulation to application of compression bandaging. This is 
not unduly prolonged when compared with several EVLT only series. Gerard 
and colleagues reported an average duration of 60 minutes to perform EVLT 
alone (Gerard, Desgranges et al. 2002). It is realised that length of procedure is 
dependent on length of treated vein and operator experience, and some authors 
have reported much shorter average procedure times of about 30 minutes 
(Christenson, Gueddi et al. 2010) . It is however, an important point to note that 
combining phlebectomy with laser ablation does not significantly prolong the 
procedure.   
At 3 months scan, 2 limbs (4%) demonstrated reflux in the proximal segment of 
the GSV. Reflux was defined as a retrograde flow of >0.5 seconds, as 
recommended for superficial veins. These 2 cases were performed early in the 
series, and were associated with total laser energy delivery below the 
recommended 70 J/cm for technical and clinical success (Proebstle, Gul et al. 
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2003). These 2 patients went on to have repeat laser ablation. It must however 
be said, that a few other veins treated with less than 70 J/cm remained 
occluded at 3 months, thus suggesting that other factors may have contributed 
to the early failure. Besides the energy delivery, other factors have been 
suggested to lead to failure of occlusion, or early recanalisation. Prince and 
Colleagues studied the impact of laser fibre design on the outcome of EVLA, 
and found that the use of the standard bare-tip fibre was associated with a 
treatment failure rate of 2.3%, compared with 11.1% using the newer gold-tip 
NeverTouch VenaCure laser fiber (AngioDynamics, Queensbury, NY) (Prince, 
Soares et al. 2011). Other investigators have that a large vein size, which may 
be difficult to compress fully against the laser fibre with tumescent fluid, leads to 
treatment failure (Kontothanassis, Di Mitri et al. 2009, Myers and Jolley 2009). 
The use of a continuous laser mode has also been suggested to be more 
effective that the pulsed mode (Rasmussen, Bjoern et al. 2007).  
In the EVLTAP study, SFJ occlusion was defined as flush occlusion of the GSV 
at the SFJ with any “knobbing” or stump no greater than 5 mm. Although GSV 
occlusion is more significant than SFJ occlusion following EVLT, we chose to 
monitor SFJ occlusion because of the possibility of developing reflux in the 
tributaries around the SFJ if it is not occluded or is incompetent. Most 
practitioners of EVLA would recommend commencing laser ablation about 1 – 
2cm proximal (caudal) to the SFJ to prevent thrombus extension into the 
common femoral vein (Khilnani, Grassi et al. 2010). Using this technique of 
flush occlusion did not result in any definite case of thrombus extension into the 
  
150 
 
common femoral vein (CFV) in this series, or in the over 100 limbs treated up to 
the time of data collection, but not included in the EVLTAP series. We have had 
one case of a small eccentric thrombus in the CFV close to the SFJ, which was 
not contiguous with the non-thrombotic occlusion of the GSV. This may have 
been due to migration of the tip of the laser fibre during tumescent anaesthetic 
infiltration. It is pertinent to state however that we scanned our patients at 1, 6, 
and 12 weeks, whereas, earlier scanning (within 72 hours) appears to identify 
more cases of sub-clinical deep vein thromboses (Khilnani, Grassi et al. 2010). 
At the 6 week follow up, three patients had thread veins that had become more 
prominent post laser ablation, while one patient had several small residual 
varices. None of these patients had duplex ultrasound scan evidence of 
treatment failure (non-occlusion or re-canalisation of the treated segment of 
vein). The patients with thread veins underwent successful treatment with liquid 
sclerotherapy. The single patient, who had residual varices, successfully 
underwent further ambulatory phlebectomy. These four limbs accounted for 
fewer than 6% of the 68 limbs seen at 6 weeks. This represents a vast 
reduction in the reported 30% - 99% of patients who require subsequent 
adjunctive procedures following EVLT only.   
EVLTAP was associated with high levels of patient satisfaction with cosmetic 
appearance and overall treatment. Satisfaction was assessed in 2 areas to 
show that in addition to cosmetic outcome, patients were also satisfied with the 
whole EVLTAP procedure, and found it acceptable. Most previous studies have 
assessed patients’ acceptance of EVLT in various ways, usually qualitatively, 
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and like our study, they have demonstrated an overwhelming acceptance of 
EVLT. 
The EVLTAP study was a prospective observational series. When the results 
were first presented and published, the main criticism was that no comparison 
had been made with EVLA – only procedure. While this was accepted as a ‘fair 
enough’ criticism, it needed to be appreciated that this was a study to assess 
feasibility and acceptance of the modification of a new technique. As the results 
showed, although no direct comparison was made at that time, the concerns for 
patient discomfort, safe dose of anaesthetic and prolonged duration of the 
procedure, have not been borne out. 
In summary, we have found the combined procedure of EVLTAP to be a 
feasible option, and an alternative to “EVLT only” procedure. EVLTAP is not 
unduly prolonged, and not associated with pain that may limit immediate return 
to normal activities. It is acceptable to patients, and vastly reduces the number 
of sequential treatments required. Since this study was completed, there have 
been several other reports of combining EVLA with phlebectomy, perforator 
surgery, foam sclerotherapy and high ligation (Florio, Del Papa et al. 2008, Kim, 
Kim et al. 2009, Christenson, Gueddi et al. 2010). 
 In 2007, EVLA was a relatively new treatment for varicose veins. The main aim 
of treatment for varicose veins is to improve QoL and prevent / treat 
complications. The benefit of any new treatment must be gauged against the 
current “gold standard”, which in this case is surgery. Whilst current evidence 
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supporting EVLA for varicose veins provides acceptable GSV occlusion rates 
and patient acceptability, at that time, QoL outcomes were lacking. Successful 
treatment must take into account, patients’ perception of benefit, assessed by 
QoL measures or satisfaction surveys (McDaniel, Nehler et al. 2000). We 
therefore designed a study to investigate not just clinical and technical 
outcomes, but especially QoL outcomes post EVLA. The prospective non 
randomised study was designed as a pilot study, to generate data which would 
be utilised in a planned randomised trial. At that time, that was the first study to 
analyze QoL outcomes following EVLA, and to compare these to the QoL 
outcomes following current gold standard treatment. 
As this was a non-randomized trial, baseline intergroup differences were not 
unexpected. Analysis of co-variance, a technique that reduces bias in 
comparative studies, was performed to adjust for these baseline differences 
(Anderson, Auquier et al. 1980). 
A significant decline in QoL was observed in the surgery group at 1-week post 
procedure. No such decline was observed following EVLA. Also, intergroup 
comparisons demonstrated significant QoL differences at the 1 and 6-week time 
points particularly in the physical SF36 domains. This suggests that the 
deleterious effects of surgery for varicose veins on patients’ early QoL are not 
seen following EVLA. This is supported by EVLA case series, which have 
shown almost immediate return to normal activities. Thus the early physical 
benefits following minimally invasive EVLA are clear in comparison with 
surgery.   
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Many of the generic QoL scores in both groups improved significantly at 6 and 
12 weeks. This demonstrates that the QoL benefits following varicose vein 
surgery are also seen following EVLA, with no difference at 12 weeks. 
The disease-specific QoL analysis demonstrated some important variation in 
comparison with the generic QoL analysis. The decline in QoL at 1 week was 
statistically significant in both groups, whereas the decline in the SF-36 domain 
scores at 1 week following EVLA did not reach statistical significance. This 
difference is perhaps not unexpected. The AVVQ is a disease-specific 
instrument, and therefore generally accepted to be more responsive to change 
in varicose vein status. In addition, the AVVQ ascribes points for compression 
therapy. All patients in this study were advised to wear compression stockings 
for 6 weeks post intervention, potentially artificially increasing the AVVQ score. 
The routine prescription of pain relieving tablets may also have contributed to 
the increased AVVQ scores. 
As seen in the SF-36 analysis, both groups experienced significant 
improvement in overall QoL following treatment for their disease. This adds to 
the body of evidence that varicose vein treatment improves patients’ quality of 
life. It has to be said however, that the EVLA group experienced a higher AVVQ 
improvement at 12 weeks. This may indicate that as far as disease-specific QoL 
assessment is concerned, EVLA is better than surgery. However, the surgery 
group had higher AVVQ scores at baseline, and the difference between the 
groups at 12 weeks may represent residual venous insufficiency in this group, 
which had more symptomatic disease to begin with.  
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The improvement of our patients was not limited to QoL outcomes. As seen by 
the venous clinical severity scores, there was a significant improvement in the 
severity of our patients’ disease. This improvement was similar at 12 weeks in 
both groups, and highlights the efficacy of both modalities of treatment. The 
majority of our patients in both groups had uncomplicated varicose veins (C2 
CEAP classification), and specifically, none had active ulceration. However, in a 
series of 23 patients with varicose ulcers, EVLA without long-term compression 
resulted in ulcer healing in 22 patients, in a median time of 4 months (Sharif, 
Soong et al. 2006). There is therefore potential for EVLA to be effective in 
treating more severe disease.  
The results must be interpreted in light of some limitations. Firstly is the fact that 
it was a non – randomised trial, and therefore subject to bias in terms of patient 
matching. This is a justified criticism; however the patient selection was based 
on previously detailed criteria, and no deliberate attempts were made to select 
the best patients for EVLA. Also, the patients were fairly well matched as can be 
seen from the baseline parameters, and during analysis of the results, an 
analysis of co-variance was performed to adjust for any baseline differences. It 
is however appreciated that this technique may not completely eliminate all 
bias. Another criticism was that the surgery cases were performed by different 
surgeons, including Specialist Registrars, while the EVLA cases were 
performed by a single consultant. Although it can be argued that there would be 
operator variability in the surgical cases, the fact was that all the surgeries were 
performed in a standard way, as practiced by the majority of vascular surgeons 
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in the UK, and the variability was minimal. Again, only about half of 62 patients 
in the surgery group had 12 week follow up. Whether or not this proportion was 
representative of the group can only be speculated upon. 
In conclusion, this study highlighted firstly, both surgery and EVLA for varicose 
veins improve QoL, an important consideration for medical managers and policy 
makers during decision-making regarding resource allocation and service 
provision: varicose veins are not just a cosmetic problem. Secondly, in the early 
post intervention period, EVLA has a QoL advantage over surgery. Although 
this advantage becomes progressively reduced with time, it may have 
significant implications in terms of early return to normal lifestyle and activities. 
Even given this study’s limitations, we believe it highlights important findings 
that need to be further investigated by a randomized clinical trial with prolonged 
follow up. In the period since this study was performed, our unit has gone on to 
investigate and compare QoL outcomes between surgery and EVLA in a 
randomised trial setting (Carradice, Mekako et al. 2011); The findings are 
similar. This confirms that EVLA definitely has QoL outcome advantages over 
standard surgery, especially in the early post intervention period.   
Since the introduction, expansion of indications, and utilisation of minimally 
invasive therapies for varicose vein treatment, there has been a challenge to 
the concept of standard surgery being the gold standard treatment for varicose 
veins. However, at least for now, open varicose vein surgery, introduced by 
Babcock in the early 1900s, and modified over the years, remains the gold 
standard. Surgery is effective in eliminating varicosities, eradicating or 
  
156 
 
ameliorating symptoms, and restoring quality of life (MacKenzie, Paisley et al. 
2002, Carradice, Mekako et al. 2011). When performed in a day case setting, it 
is also cost effective (Gohel, Epstein et al. 2010). Standard surgery however 
has important limitations. One such limitation is the fact that unlike the minimally 
invasive procedures which are usually performed under local anaesthetic in an 
office setting, surgery usually requires a general anaesthetic and an operating 
theatre. Although there are reports of performing groin dissection under local 
anaesthetic with or without sedation, and stripping the great saphenous vein 
under tumescent fluid infiltration (Rasmussen, Lawaetz et al. 2011), the 
standard practice is a general anaesthetic procedure.  
Another limitation of surgery is the potential for wound problems, of which groin 
wound infection is most significant. Varicose vein surgery would be classified as 
clean surgery, and therefore have an estimated wound infection rate of 1 - 5% 
(Garner, Jarvis et al. 1988). Several series however, have variously reported 
higher rates of wound infection, reaching 16% in the series by Hayden and 
Holdsworth who investigated complications of groin re - exploration for recurrent 
varicose veins (Hayden and Holdsworth 2001). There is a likelihood that 
reported infection rates may reflect under representation, as currently, the vast 
majority of varicose vein operations are performed as day cases, with any 
wound infections manifesting in the community (Grogaard, Kimsas et al. 2001), 
often without the knowledge of the operating surgeon. When routine post - 
discharge surveillance is carried out, higher infection rates are reported. This 
fact was well highlighted by Avato and Lai who investigated the impact of post - 
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discharge surveillance on surgical site infection rates for coronary artery bypass 
procedures (Avato and Lai 2002). They found that only 28% of their total wound 
infections were diagnosed prior to discharge, with 78% manifesting in the 
community, after patients were discharged from hospital. The true rate of 
surgical site infections (SSIs) following varicose vein surgery is therefore not 
known. 
Amongst surgical patients in the United Kingdom, surgical site infections are the 
commonest form of hospital acquired infection (Nosocmial Infection National 
Surveillance Service 2001). It is estimated that about 10% of patients in the UK, 
and 38% of patients in the USA experience SSIs each year (Mangram, Horan et 
al. 1999, Nosocmial Infection National Surveillance Service 2001). Prevention of 
SSIs depends to a large extent on critical factors such as surgical techniques 
and the general health and co morbidity of patients. However, the efficacy of 
prophylactic antibiotic use in reducing the risk of SSIs has long been 
demonstrated (Polk H C Jr and Lopez-Mayor J F 1969). In fact, it is estimated 
that 40% - 60% of SSIs are preventable by timely administered appropriate 
prophylactic antibiotics (Mangram AJ, Horan TC et al. 1999). 
Surgical wound morbidity is not limited to infection, and many conventional 
definitions of SSI may be restrictive and not account for small, but significant 
patient – centred aspects of wound morbidity (Hall, Willsher et al. 2006). The 
use of wound scoring methods, of which the ASEPSIS is arguably the most 
widely used, in part overcomes this (Bruce, Russell et al. 2001). 
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Currently, there is disagreement among the several recognised definitions of 
SSIs, such that wounds that are classed as infected by one definition, may be 
classed as not infected by another (Wilson, Gibbons et al. 2004). The guideline 
from the Centres for Disease Control and Prevention (CDC) (Horan, Gaynes et 
al. 1992) for example, allows a definition of superficial SSI to be made on the 
basis of purulent drainage, while the ASEPSIS method defines infection as a 
total score of ≥ 21. In our study of antibiotic prophylaxis in varicose vein 
surgery, patients reported purulent discharge from 10.4% of wounds in the 
treatment group and 20.1% in the control group. If we defined wound infection 
using the ASEPSIS method, then 9.9% of the groin wounds in the treatment 
group and 18.2% of the control group would be classed as infected. These 
proportions satisfying both definitions are very similar, and show agreement 
between the ASEPSIS and CDC definitions in this trial; this would appear to 
validate our assessments and results. Whereas many ambulatory surgeons will 
claim low wound infection rates in clean surgery, the evidence in fact, is that 
many infections manifest in the community and are therefore undetected by the 
surgeon; these cannot be identified without adequate post-discharge wound 
surveillance (Reimer, Gleed et al. 1987, Weigelt, Dryer et al. 1992). Our results 
are in keeping with surveillance reports for clean wound SSI rates, and are not 
excessive. 
With most infections manifesting post hospital discharge, community care 
practitioners (GPs and district nurses) take on the responsibility of managing 
these infections with consequential time and resource implications 
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(Perencevich, Sands et al. 2003). In our study, significantly more patients in the 
control group consulted their GPs for wound problems, and received antibiotics 
for perceived wound infections. Bjerrum et al have previously demonstrated that 
there is a degree of inappropriate antibiotic prescription by general practitioners, 
which is changed by education and training (Bjerrum, Cots et al. 2006). Even if 
it is argued that some antibiotic prescribing by GPs in our trial may have been 
inappropriate, it is pertinent however, that half of all patients who visited their 
GPs did not receive antibiotics. It is evident in our study, and worthy of note, 
that the use of prophylactic antibiotics resulted in significant reduction in the 
burden of postoperative wound management placed on primary care 
(evidenced by fewer visits to GPs, and fewer antibiotics prescribed). 
The patient-dependent variables identified as predictors for poor wound 
outcome, namely high BMI and current cigarette smoking, are consistent with 
previous findings. (Sorensen, Horby et al. 2002, Itani, Wilson et al. 2006). We 
found female gender to be significantly associated with a good wound outcome 
in one multivariable model. This is contrary to the findings in Lichtenstein hernia 
repair (Aufenacker, van Geldere et al. 2004). However, in a study of antibiotic 
prophylaxis in patients undergoing elective colorectal surgery, male gender was 
significantly associated with the odds of a poor wound outcome (Itani, Wilson et 
al. 2006). Whether these findings are because men have a higher nasal 
carriage of Staphylococcus aureus, (Herwaldt, Cullen et al. 2004) or that 
hygiene is poorer in men, can only be speculative. Like others, we found that 
the administration of prophylactic antibiotic was an independent predictor of a 
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good wound outcome (Esposito, Leone et al. 2006, Itani, Wilson et al. 2006). 
Other studies have found significant associations between poor wound 
outcomes and age, (Bertin, Crowe et al. 1998) but our trial did not show this. 
We also did not find clinical class of varicose veins to have any association with 
poor wound outcomes. Antibiotic prophylaxis, high BMI and current smoking, 
remained significant independent variables associated with wound outcomes on 
patient-based modelling.  
Due to the small number of patients with diabetes and those on steroids in our 
trial, these factors were not analysed for association with poor wound outcome. 
We also did not consider non-patient dependent variables (e.g. length of 
operation, surgeon’s experience) which are recognised to be associated with 
poor wound outcomes. Day case provision for varicose vein surgery in our unit 
is consultant-led, with close supervision of higher surgical trainees. This results 
in minimal variability in experience and procedure duration. 
The CDC stipulates a postoperative period of 30 days for making a definition of 
superficial SSI in non-implant wounds, and this has been used by many studies. 
However, about 90% of surgical wound infections manifest within three weeks 
post operatively, (Weigelt, Dryer et al. 1992) and in a study of antibiotic 
prophylaxis in clean groin surgery, all of the patients who developed SSI, did so 
in the first 7 days (Perez, Roxas et al. 2005). In our study, patients performed 
wound assessments up to the 10th postoperative day, and a blinded 
investigator reviewed all groin wounds at 14 days. We found a steady decline in 
reported wound problems, with the passage of time; such that on day 14, only a 
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relatively small proportion of patients had any wound problem. The deduction is 
that late onset wound morbidity would appear to be negligible. Therefore, 
although our period of observation was relatively short, we were likely to have 
detected the vast majority of patients with wound morbidity. 
In investigating the effect of antibiotic prophylaxis in wound related 
complications post varicose vein surgery, this study used the ASEPSIS criteria 
for assessing wound problems. This method of scoring has been criticised as 
being over sensitive and may actually over call wound infection. This system 
however, is validated and is probably the most robust method of assessment. A 
criticism of the use of this system in this study would be the method of wound 
assessment. Whereas in the original design of the ASEPSIS wound 
assessment was carried out by healthcare personnel on an in-patient basis, it 
was necessary in this study to ‘train’ patients on self-assessment, due to the 
day – case nature of varicose vein surgery. This “limitation” has already been 
addressed in the discussion. 
There are important highlights arising from this RCT. We have demonstrated 
that a significant proportion of patients undergoing surgery for varicose veins 
suffer groin wound morbidity. These problems usually manifest in the 
community and thus are managed by primary care providers, increasing 
pressures on time, manpower and resources. We have also demonstrated that 
the use of prophylactic antibiotics significantly reduced the wound morbidity, 
visit to a GP for postoperative wound problems, and the requirements for further 
antibiotics for postoperative wound infection. A high BMI and current smoking 
  
162 
 
are important patient-dependent factors significantly associated with a poor 
wound outcome. In light of these findings, we conclude that prophylactic 
antibiotics are beneficial in patients undergoing groin surgery for varicose veins, 
and should be routinely administered; especially if patients are obese and 
current smokers. 
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FUTURE PERSPECTIVES 
There has been tremendous development in the area of varicose vein 
management since the time of the commencement of the studies contained in 
this thesis. During the initiation of these studies, ‘the future’ looked towards 
aspects such as ablation of small saphenous vein (SSV) varicosities, and of 
major tributaries such as anterolateral thigh veins (anterior accessory GSV). 
Also the future looked at comparing laser ablation with standard surgery in the 
setting of randomised trials. These are now the present, and in some respects, 
are now the ‘past’. As has already been alluded to in the text, it is now routine to 
perform laser ablation for SSV and anterior accessory GSV varicosities. 
Several units, including ours, have performed randomised comparisons of laser 
ablation with standard surgery. We found similar improvement in the venous 
clinical severity scores of patients, following treatment with both surgery and 
laser ablation. Of significance however, was that the quality of life impairment 
associated with standard surgery in the immediate and early post operative 
period, was absent with laser ablation (Carradice, Mekako et al. 2011), a finding 
which had already been noted in study 3 of this present work (Mekako, Hatfield 
et al. 2006). This led to earlier return to work and usual activities in patients 
undergoing laser ablation as compared to surgery.  
Another advance that has occurred is in the utilisation of higher wavelength 
lasers. The studies in this thesis were performed using the 810nm diode laser. 
Higher wavelength lasers – 940nm, 980nm, 1320nm, 1470nm, and 1560nm – 
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have been trialled and now being utilised (Munavalli and Weiss 2006, 
Desmyttere, Grard et al. 2010, Pannier, Rabe et al. 2011). The lower 
wavelength lasers have affinity for haemoglobin and the absorption of heat by 
the haemoglobin in the red cells causes blood to boil, and the ‘steam bubbles’ 
thus generated, transfer energy to the vein wall. It is believed that the prolonged 
contact of these bubbles with the vein wall, as well as the direct effect of the 
heated laser fibre, results in vein wall perforation and charring, which contribute 
to the significant bruising and post procedural pain associated with the lower 
length lasers (Munavalli and Weiss 2006). The higher wavelength lasers have 
an affinity for water, and have been noted to cause up to 80% less bruising and 
pain than the lower wavelength fibres (Munavalli and Weiss 2006). There is 
however no unequivoval evidence to support superiority of any particular fibre 
wavelength.  
The design of the laser fibres has also seen advances. The first laser fibres 
were bare-tipped, and these were utilised in the studies in this thesis. There 
have been developments aimed at reducing the vein wall contact by the laser 
tip, which was thought to cause charring and perforation of the vein wall, with 
resultant vein wall perforation and increased post procedure pain and bruising. 
Developments have seen the introduction of a ‘jacket’ to cover the bare tip (the 
jacket-tip fibre) as well as glass, ceramic, diffusion and radial fibres. These are 
thought to result in a more uniform transfer of energy to the vein wall, and 
therefore less vein wall perforation. Short term follow up has shown promise of 
less bruising, less pain, and equal efficacy with the bare-tip fibres (Doganci and 
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Demirkilic 2010), although some evidence of more treatment failures have been 
reported (Prince, Soares et al. 2011). 
In November 2008, the CLASS (Comparison of LAser, Surgery and foam 
Sclerotherapy as a treatment for varicose veins) trial started recruitment. This is 
a multicentre randomised trial which compares minimally invasive treatment 
(laser and foam sclerotherapy) with surgery, with primary outcomes of clinical 
and cost effectiveness. The trial is ongoing, and the results are expected with 
anticipation, as it is hoped that un-biased answers will be provided. 
The future perspectives from this point on, will be exploring long term outcomes 
with the use of higher wavelength fibres, lower energy delivery, newer designs 
of laser fibres, as well as cost effectiveness of EVLA as compared with other 
modalities of therapy – both conventional and minimally invasive.    
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IMPACT OF THIS WORK 
The studies included in this thesis commenced in the early days of endovenous 
laser ablation of varicose veins. At the time, evidence was sparse and limited to 
a few case reports and case series, with no high level evidence directing 
practice.  
The EVLTAP paper described a modification and adaptation of endovenous 
laser ablation. The paper won the second prize in the “poster of distinction” 
session of the Association of Surgeons of Great Britain and Ireland (ASGBI) 
annual conference in 2006. More importantly, it led to the design and 
performance of a randomised trial (Carradice, Mekako et al. 2009) by this unit 
and the adoption of EVLTAP practice by other units (Gloviczki, Comerota et al. 
2011). 
The non randomised trial of EVLA versus surgery study led on to the design 
and performance of several randomised trials which have contributed 
immensely to the literature. 
Since the publication of the paper on antibiotic prophylaxis for varicose vein 
surgery, our unit has adopted the use of single dose antibiotic prophylaxis for 
varicose vein surgery. The adoption has seen a reduction of wound 
complications following varicose vein surgery (un - published in house audit).  
In summary, the work contained in this thesis was fairly ground – breaking work 
at the time it was done. It formed the pilot data for future RCTs which were 
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performed within the Academic Vascular Unit in Hull, resulting in several prize 
presentations (Venous Forum, Vascular Society of Great Britain and Ireland) 
and led to papers published in high impact factor surgical journals. This 
resulting work contributed significantly (the largest published RCT of 
endovenous ablation verses surgery) to the body of evidence which has 
resulted in a huge sea of change in the way vascular surgeons manage 
superficial venous incompetence with generally >50% of cases being managed 
with an endovenous approach. Thus although now perhaps a little dated, the 
data presented in this thesis represents the foundations on which this huge 
change in clinical practice was based, and thus merits recognition.   
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SUMMARY AND CONCLUSION 
The invasive treatment of lower limb varicose veins has evolved since Babcock 
first described a new way of extirpation of varicose veins of the Leg in 1907. 
Several developments and modifications of open surgery, including PIN 
stripping, cryostripping, etc, have made current day open surgery for varicose 
veins clinically effective, quite safe, and cost effective. It remains one of the 
most commonly performed surgical procedures in the developed world, and the 
“proven” gold standard as far as treatment of varicose veins is concerned. 
Arguably the most significant development in varicose vein management came 
in the mid to late 1990s with the introduction of minimally invasive therapies in 
the form of endovenous thermal ablation. Of these techniques, endovenous 
laser ablation has undergone the greatest revolution and clinical application. 
EVLA mostly uses diode laser energy to cause thermal damage to the venous 
endothelium and subsequent non – thrombotic occlusion of the treated vein. It 
has proved to be as effective as, and possibly more effective than standard 
surgery, in terms of abolition of reflux and prevention of recurrent disease. 
Despite the enthusiasm that greeted the introduction of EVLA, and the desire to 
widen its application, in its early days, it was largely applied mainly to the 
treatment of reflux in the GSV. However, not all veins can be treated by EVLA, 
as some are anatomically unsuitable. When we performed our initial EVLA 
suitability study in 2005, using extremely tight criteria, only 56% of veins were 
found suitable. In the period since our feasibility study was carried out, the 
indications and utilisation of laser ablation have expanded tremendously. It is 
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now routine to perform laser ablation on small saphenous vein, anterior 
accessory GSV, recurrent varices, small calibre veins, and perforating veins. 
Very tortuous, small sized and superficial veins remain a challenge to the utility 
of EVLA.  
The “standard” practice of EVLA is to perform truncal vein laser ablation only, 
and carry out any required tributary varicosity treatment subsequently. This 
means more than one treatment visit for most patients. This may be a relative 
“dissuasion” for patients, especially for those who need to take time off work. 
Study 2 of this work showed that it was both feasible and indeed acceptable to 
patients to combine EVLA with mini phlebectomy as a one - stage procedure. 
This practice (or a modification of it) has been taken up by several other 
practitioners in current day varicose vein management.  
The monitoring of outcomes of the treatment of varicose veins has gone beyond 
technical and “clinical” success. Quality of life measures are now an integral 
part of outcome analyses. EVLA improves QoL in sufferers of varicose veins. 
This was clearly demonstrated in study 3: a non randomised controlled trial of 
EVLA and surgery in treatment of GSV varicosities. EVLA produced better QoL 
preservation and improvement especially in the early post intervention period, 
than did open surgery. This is an important effect, especially in the current 
economic climate, as it ensures earlier recovery and return to work following 
varicose vein treatment.  
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EVLA avoids the need for a groin incision and therefore eliminates the potential 
for a groin wound infection. Although varicose vein surgery is clean surgery, 
there remains a risk for surgical site infections and other wound complications. 
The use of prophylactic antibiotics has been shown in various settings to be 
effective in preventing or reducing the incidence of surgical site infections. 
Study 4 of this work looked specifically at this, in the setting of varicose vein 
surgery. The findings were clear and important: the use of prophylactic antibiotic 
significantly reduced wound complication, and the need to visit general 
practitioners and require antibiotics in the post operative period. 
In the delivery of modern day surgical services, the trend towards less invasive 
interventions is clearly obvious. This is driven by patient, surgeon, and hospital 
management preferences, (possibly) imposed by the current economic climate. 
The hope (or assumption) is that the less invasive interventions would lead to a 
reduction in complications, length of hospital stay, and cost. The delivery of 
varicose vein services has towed the same line as the rest of surgery (and 
indeed Medicare). What is gratifying (and this is demonstrated in this work), is 
that EVLA as a frontline less invasive option, has fulfilled this hope. Although 
this present work did not include calculation of costs, other reports have shown 
that EVLA is cost effective. It therefore fulfils an ideal intervention for varicose 
veins, meeting important outcomes and qualities: 
It is effective in abolishing reflux in the treated vein 
It causes clinical improvement and eradication of symptoms 
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It is very safe, with few complications 
It preserves and improves health related quality of life 
It is cost effective 
It is highly acceptable to patients 
As already alluded to, not every patient or every varicose vein will be suitable 
for laser ablation; therefore surgery would still play an important role in 
management of varicose veins. The growth in the use of foam sclerotherapy 
(although not specifically studied in this work), means that there is yet another 
tool for the treatment of suitable veins and patients. There is as yet no one-cap-
fits-all modality, and although almost any varicose vein can be treated by 
surgery, not all patients will want to have, (nor indeed can be candidates to 
have) open surgery. In spite of its current status as gold standard, it is inevitable 
that the role of standard surgery in the treatment of lower limb varicose vein will 
shrink significantly in the nearest future, in line with the expansion of minimally 
invasive techniques. 
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Appendix 1: venous clinical severity score 
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Appendix 2: Aberdeen varicose vein questionnaire 
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Appendix 3: Short Form 36 
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